A vasoregulatory cytokine

CXCL14-derived peptides selectively activate AGTR2 and BDKRB2 to regulate vascular tone and reduce hypertension, addressing limitations of current RAAS medications by enhancing vascular integrity and reducing cardiac remodeling without side effects.

WO2026236701A1PCT designated stage Publication Date: 2026-11-12THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027432
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current medications targeting the renin-angiotensin-aldosterone system (RAAS) for cardiovascular and renal diseases have limitations, including side effects like angioedema and sodium retention, and there is a need for selective activation of Angiotensin II Type 2 receptor (AGTR2) and Bradykinin B2 receptor (BDKRB2) to regulate vascular permeability and tone without activating AGTR1 or BDKRB1.

Method used

Development of polypeptide fragments from the C-terminal region of CXCL14 that act as selective agonists or inhibitors of AGTR2 and BDKRB2, modulating vascular tone and reducing hypertension, while avoiding activation of AGTR1 and BDKRB1, and incorporating modifications for enhanced stability and administration.

Benefits of technology

The CXCL14-derived peptides effectively reduce hypertension, prevent cardiac remodeling, and enhance vascular integrity, providing antihypertensive and cardioprotective effects without the side effects associated with existing RAAS inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000019_0001_TABLE
    Figure IMGF000019_0001_TABLE
  • Figure IMGF000020_0001_TABLE
    Figure IMGF000020_0001_TABLE
  • Figure 00000073_0000
    Figure 00000073_0000
Patent Text Reader

Abstract

Peptide fragments of the chemokine CXCL14 are shown herein to be pro-agonists of AGTR2 and BDKRB2. The peptides are activated by proteolytic cleavage at the C terminus of the chemokine. Peptides from the C terminus of CXCL14 are sufficient to activate BDKRB2 / AGTR2 and may inhibit activity of Angiotensin II Type 1 receptor (AGTR1) or Bradykinin B1 receptor (BDKRB1).
Need to check novelty before this filing date? Find Prior Art

Description

A VASOREGULATORY CYTOKINEGOVERNMENT SUPPORT RESEARCH

[0001] This invention was made with Government support under contract AI047822 and AI178113 awarded by the National Institutes of Health. The Government has certain rights in the invention.INCORPORATION BY REFERENCE OF SEQUENCE LISTING PROVIDED AS A SEQUENCE LISTING XML FILE

[0002] A Sequence Listing is provided herewith as a Sequence Listing XML, “STAN- 2266WO_seqlist”, created on May 8, 2026 and having a size of 37,528 bytes. The contents of the Sequence Listing XML are incorporated herein by reference in their entirety.BACKGROUND

[0003] The renin-angiotensin-aldosterone system (RAAS) is a critical regulator of blood volume, electrolyte balance, and systemic vascular resistance. While the baroreceptor reflex responds in the short-term to decreased arterial pressure, the RAAS is responsible for acute and chronic alterations. The classical understanding of RAAS is that it comprises 3 significant compounds: renin, angiotensin II, and aldosterone. These 3 compounds elevate arterial pressure in response to decreased renal blood pressure, salt delivery to the distal convoluted tubule, and beta-agonism. The RAAS is ubiquitous and involves multiple organ systems, especially the kidneys, lungs, systemic vasculature, adrenal cortex, and brain.

[0004] The juxtaglomerular cells, present within the afferent arterioles of the kidney, contain prorenin. Activation of juxtaglomerular cells causes the cleavage of prorenin to renin. The activation of prorenin occurs in the kidney by enzymes like proconvertase 1 and cathepsin B. Mature renin is stored in the granules of the juxtaglomerular cells and released into circulation by various stimuli, including negative feedback from humoral factors like angiotensin I, potassium (renin release is increased by hypokalemia and decreased by hyperkalemia), and ANP (atrial natriuretic peptide). Renin is the ratelimiting enzyme in RAAS.

[0005] Angiotensinogen is primarily synthesized and constitutively secreted by the liver. Renin cleaves the angiotensinogen's N-terminal and leads to angiotensin I's formation. Angiotensin-Converting Enzyme (ACE) is expressed on plasma membranes of vascular endothelial cells, primarily in the pulmonary circulation. It cleaves the 2 amino acids from the C-terminal of angiotensin I to make the peptide angiotensin II. Angiotensin II is the primary mediator of the physiologic effects of RAAS, includingblood pressure, volume regulation, and aldosterone secretion. The half-life of angiotensin II in circulation is very short, less than 60 seconds.

[0006] The physiological effects of angiotensin II on extracellular volume and blood pressure regulation are mediated by multiple pathways, including vasoconstriction by contraction of the vascular smooth muscle in the arterioles, aldosterone secretion from the adrenal cortex, increased sodium reabsorption through increased activity of the Na-H antiporter in the proximal convoluted tubule, increased sympathetic outflow from the central nervous system, and release of vasopressin.

[0007] Angiotensin II Type 1 Receptor (AT1 R) is a G-protein coupled receptor. It is widely distributed in many cell types, including the heart, vasculature, kidney, adrenal glands, pituitary, and central nervous system. Angiotensin II mediates its physiological effects of vasoconstriction and sodium and water reabsorption through the AT1 R. In pathogenic states, the activation of the AT1 R leads to inflammation, fibrosis, oxidative stress, tissue remodeling, and increased blood pressure. The dysregulation of this receptor is central to the pathophysiology of cardiac and renal diseases.

[0008] Angiotensin II Type 2 Receptor (AT2-R) is a G-protein coupled receptor. It is highly expressed in fetal tissues, and expression decreases in adulthood. In adults, it is distributed in but not exclusive to the heart, kidney, adrenal glands, and brain. AT2R mediates the opposing and protective effects of angiotensin II countering those of the AT1-R. These AT2R actions inhibit inflammation, fibrosis, and central sympathetic outflow and cause vasodilation. Stimulation of AT2R by angiotensin II leads to vasodilation and natriuresis, opposite to the vasoconstriction and anti-natriuresis caused by angiotensin II signaling through AT1 R. AT2R activation has been linked to tissue protection and repair across cardiovascular, renal, and neural systems — including reduction of oxidative stress, attenuation of apoptosis in vascular and neuronal cells, and promotion of endothelial regeneration. AT2R-mediated vasodilation and many of its anti-inflammatory effects are partially dependent on bradykinin and nitric oxide release, reflecting functional cross-talk with the B2R pathway. Selective AT2R agonists, exemplified by Compound 21 , have demonstrated preclinical efficacy in models of cardiovascular, renal, and neural injury, and have entered clinical development for fibrotic and inflammatory lung disease. Bradykinin is a product of the kallikrein-induced breakdown of high-molecular-weight kininogen (HMWK) in the kinin cascade, which is inactivated by angiotensin-converting enzyme (ACE) in the lungs and kidneys. Bradykinin plays a prominent role in acute inflammation. Bradykinin, along with prostaglandins and histamine, are mediators of vasodilation, in which the arteriolar smooth muscle relaxes and, in turn, increases blood flow. This increased blood flow causes the rubor, or redness, and calor, or warmth, components of the inflammationprocess. Bradykinin, along with prostaglandin E2 (PGE2), also plays a role in the sensitization of sensory nerve endings, which causes dolor, or pain. Thus in the acute response to inflammation, bradykinin causes an increase in vasodilation, an increase in permeability, and an increase in pain.

[0009] Beyond its role in acute inflammation, bradykinin signaling through B2R contributes importantly to cardiovascular homeostasis and protection. Tonic endothelial B2R activation stimulates nitric oxide (NO) and prostacyclin production, supporting baseline vasodilation, regulation of vascular tone, and endothelial barrier integrity. B2R signaling counter-regulates the renin-angiotensin system, opposing AT1 R-mediated vasoconstriction and pro-fibrotic remodeling, and is implicated in the cardioprotective effects of ACE inhibitors, which act in part by elevating local bradykinin availability. B2R activation has also been linked to protection against cardiac ischemia-reperfusion injury, ischemic preconditioning, anti-fibrotic remodeling in heart and kidney, and natriuretic and renal-protective responses. Loss of B2R signaling — through genetic deletion or chronic pharmacologic blockade — has been associated with elevated blood pressure, endothelial dysfunction, and increased cardiac fibrosis. Sustained, selective B2R agonism therefore represents a therapeutically attractive strategy for cardiovascular protection, distinct from the acute inflammatory profile of bradykinin signaling described above.

[0010] ACE is present in the lungs and the kidneys and also converts angiotensin I to angiotensin II. This conversion is acrucial step in blood pressure control as angiotensin II causes vasoconstriction and increases blood pressure and constriction of efferent arterioles in the kidneys. Therefore, inhibition of ACE has clinical application as a mechanism for decreasing blood pressure. ACE inhibitors such as captopril, enalapril, lisinopril, and ramipril all inhibit ACE. They are clinically used to manage patients with hypertension, leading to decreased mortality in patients with heart failure, patients with proteinuria, and patients with diabetic nephropathy.

[0011] Inhibition of ACE decreases the amount of angiotensin II formed from angiotensin I.This decrease in angiotensin II causes a reduction in the glomerular filtration rate by preventing the constriction of efferent arterioles. This dilation of efferent arterioles causes an increase in renin due to the loss of negative feedback. Inhibition of ACE, however, also inhibits the inactivation of bradykinin. Because bradykinin is a potent vasodilator, the prevention of bradykinin inactivation causes excessive amounts of bradykinin to build up. This increased bradykinin can cause the side effect of angioedema, which can be seen in some patients taking ACE inhibitors and is the reason for the contraindication of ACE inhibitors in C1 esterase deficiency. Clinically, angiotensin II receptor type 1 blockers (ARB) can be used instead of ACE inhibitors forblood pressure control in hypertensive patients, heart failure, proteinuria, chronic kidney disease, including diabetic nephropathy, or patients with intolerance to ACE inhibitors such as those who have excessive coughing or angioedema.

[0012] Overactivation of the RAAS has been implicated in the pathogenesis of various cardiovascular and renal diseases. RAAS is also implicated in the pathogenesis of primary hypertension. This has been proven by using medications that block the RAAS at different steps. Overactivation of the RAAS is also implicated in the development of secondary hypertension due to primary hyperaldosteronism. Primary hyperaldosteronism is the excess aldosterone production either by an adrenal adenoma (Conn syndrome) or bilateral adrenal hyperplasia producing excess aldosterone. These patients have suppressed renin, and elevated aldosterone levels, often with hypokalemia. Primary hyperaldosteronism remains an under-recognized condition with excess cardiovascular and renal morbidity and mortality.

[0013] Currently available medications targeting the RAAS include Angiotensin-Converting Enzyme inhibitors (ACE-i). Commonly used agents include lisinopril, captopril, ramipril, enalapril, fosinopril, and benazepril. These are used as first-line agents for the management of hypertension. Angiotensin Receptor type 1 Blockers (ARB) include valsartan, candesartan, irbesartan, olmesartan, and telmisartan. These are used as first-line agents for the management of hypertension. Mineralocorticoid Receptor Antagonists (MRA) such as spironolactone, eplerenone, andfinerenone have improved outcomes in patients with a history of heart failure.

[0014] Agents that selectively act on receptors in the RAAS system are of great clinical interest, and are disclosed herein.SUMMARY

[0015] Compositions and methods are provided for the regulation of Angiotensin II Type 2 receptor (AGTR2) and Bradykinin B2 receptor (BDKRB2). Polypeptide fragments of the chemokine CXCL14 are shown herein to be agonists of AGTR2 and BDKRB2. The active fragments are derived from C terminal region sequences of CXCL14. Such polypeptides are shown herein to be sufficient to activate BDKRB2 / AGTR2. Physiological effects of this activation include, for example, regulation of vascular permeability, regulation of vascular tone, reduction of hypertension, and the like. The C-terminal region sequences do not activate the closely related receptors Angiotensin II Type 1 receptor (AGTR1) or Bradykinin B1 receptor (BDKRB1). Peptides of interest may be active as an agonist of AGTR2 and BDKRB2. Peptides of interest may not activate AGTR1 and / or BDKRB1. Other peptides of interest bind to and inhibit activity of one or more of AGTR2, BDKRB2, AGTR1 and BDKRB1.

[0016] Compositions of the disclosure comprise or consist of, without limitation, peptides of CXCL14, which peptides include truncated sequences comprising at least a portion of the C-terminal region of CXCL14, modified derivatives thereof, analogs thereof, peptides with sequences similar to the C-terminal region of CXCL14, and the like. The active CXCL14 sequences for this purpose are located near the C-terminus of the protein; but lack an “inhibitory” peptide of about 9 amino acids found at the N-terminus of the protein. In an embodiment, a peptide of interest comprises at least the sequence set forth in SEQ ID NO:8. The peptides may be modified in various ways. Modifications include changes that increase peptide half-life after administration, including for example, substitution of amino acids, conjugation of the peptide to lipids, such as palmitate, conjugation of the peptide to polypeptide sequences such as Ig Fc regions, albumin, etc., pegylation, and the like. Peptides of interest include without limitation those set forth in Table 1 . In an embodiment a peptide of interest is SEQ ID NO:8, SEQ ID NO:11 , SEQ ID NO:33, or a biologically active variant thereof.

[0017] In some embodiments a polypeptide is a propeptide of an active or inhibitory C-terminal peptide of CXCL14, wherein the propeptide is activated by cleavage. Propeptides may include, without limitation, a peptide comprising or consisting of SEQ ID NO:11. The amino acid sequence may be modified to modulate activation.

[0018] In an embodiment, a CXCL14 peptide of interest is effective in reducing hypertension in an individual in need thereof. In an embodiment, a CXCL14 peptide of interest is effective in reducing risk of heart failure in an individual in need thereof, e.g. by prevention or reversal of negative cardiac remodeling, which may be measured via echocardiogram, cardiac MRI, etc. In an embodiment, a CXCL14 peptide of interest is effective in reducing risk of aneurysm.

[0019] The compositions of the disclosure are useful in treatments for diseases of vascular dysfunction including without limitation hypertension, vascular leakage in sepsis, eclampsia, ARDS, ischemic injury, cardiac remodeling and vascular complications of inflammatory diseases; aneurysm, and the like. The compositions also provide improved approaches to controlling epithelial barrier integrity for inflammatory and autoimmune diseases, such as IBD, asthma, neuroinflammation, etc. Treatment modalities also include inhibiting fibrosis. Treatment modalities also include protection and support of neurons, e.g. in controlling neurodegeneration. Treatment modalities also include enhancing wound healing.

[0020] In an embodiment an agent of the disclosure is provided as a composition for therapeutic use, e.g. in a pharmaceutically acceptable excipient. Alternatively a peptide may be provided in a lyophilized for reconstitution. The therapeutic composition may beprovided in a container, e.g. a vial. The composition may be provided in a unit dose, suitable for administration.

[0021] In an embodiment a method is provided for selective activation of one or both of AGTR2 and BDKRB2, the method comprising contacting the receptor(s) with an effective dose of an agent of the disclosure, e.g. an active peptide or propeptide. In an embodiment the agent is administered to an individual in need thereof. Activation of AGTR2 and BDKRB2 have well-established roles in promoting vasodilation, anti-inflammatory effects, tissue regeneration, and protective mechanisms against cardiovascular damage. AGTR2 activation is linked to vasodilation, anti-inflammatory effects, and reduced fibrosis. BDKRB2 activation promotes vasodilation via nitric oxide (NO) and prostacyclin. A dual BDKRB2 / AGTR2 agonist provides powerful antihypertensive and cardioprotective effects while avoiding AGTR1 -related side effects such as sodium retention and vasoconstriction.

[0022] In an embodiment, methods are provided for screening candidate agents for activity in modulating activity of AGTR2 and BDKRB2. Candidate agents include, for example, antibodies, polypeptides, aptamers, small molecules, etc., for example antibodies binding AGTR2 and / or BDKRB2, including species variants or counterparts; polypeptide sequence variants of CXCL14, including species variants, truncated sequences, modified sequences; non-peptide conjugation variants of CXCL14, e.g., glycosylation or other modifications; small molecule antagonist candidates; aptamer libraries, etc.

[0023] Compositions of the disclosure also include agents that modulate activity of CXCL14 activity in the RAAS system. Such agents include agents that bind to CXCL14, e.g. antibodies specific for active or inhibitory peptides, antibodies that compete for binding of CXCL14 peptides to cognate receptors, antibodies that bind to one or more processing sites (e.g., sites of proteolytic cleavage) in a human CXCL14 peptide, antibodies that specifically bind to an active region of the C-terminus of CXCL14, and the like. Agents may include small molecule mimetics of CXCL14. Agents may include anti-sense agents that reduce activity of CXCL14, or genome engineering agents that modify the genome structure of the CXCL14 gene. Agents include polynucleotide sequences encoding human CXCL14 peptides, which may be provided in a vector suitable for expression, genome engineering, and the like.BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The invention is best understood from the following detailed description when read in conjunction with the accompanying drawings. It is emphasized that, according to common practice, the various features of the drawings are not to-scale. On the contrary,the dimensions of the various features are arbitrarily expanded or reduced for clarity. Included in the drawings are the following figures.

[0025] FIG. 1. CXCL14 C-Term conservation: Evolutionary conservation of 68W residue in CXCL14, shown are SEQ ID NO:3, 4, 5, 6, and 7. Alignment of the C terminal alpha helical domains of the chemokine is shown for different species.

[0026] FIG. 2. CXCL14 Co-evolution analysis implicates CXCL14 in cell-cell contacts and physiologic barrier functions. The top 200 genes evolving in parallel with CXCL14 were submitted for GO term analysis (Enrichr). Co-evolution results from DEPCOD. P-value presented as -Iog10 of Benjamini-Hochberg False Discovery Rate.

[0027] FIG. 3. Bradykinin and angiotensin receptors are closely related to chemokine receptors. Dendrogram based on sequence homology.

[0028] FIG. 4. Presto-Tango p-arrestin luciferase reporter assay (co-transfection) shows selective activation of BDKRB2 and AGTR2 by SEQ ID NO:33 (the truncated chemokine ralso referred to as CXCL14 68W or X14 68W). [Note that residues of CXCL14 are numbered from the N-terminus of the mature 77-amino-acid chemokine, with position 1 corresponding to the first residue following cleavage of the signal peptide. CXCL14 peptide truncates are herein named by the position and identity of the C-terminal residue of the peptide; for example, "68W" denotes a peptide whose C- terminus is the tryptophan at position 68 of mature CXCL14.] Histograms showing luciferase reporter expression in PRESTO-Tango HTLA cells (modified HEK293) transfected with vectors encoding the indicated receptors and CXCL14 full length (SEQ ID NO:1) or truncated versions. Data (as Relative Luminescence Units (RLU)) from a representative experiment of 2-4 performed with similar results. Mean t range of technical replicates. Sequence of mature CXCL14 shown with active peptide 68W (SEQ ID NO: 8) underlined and blocking peptide in italics.

[0029] FIG. 5. Presto-Tango dose-response curves for synthetic CXCL14 C terminal peptide 68W peptide, SEQ ID NO:8 (0.003 nM -30 pM, 10-fold serial dilutions), full-length recombinant mature CXCL14 and cognate agonists (bradykinin (BK) or Des Arg BK for B2R and B1 R respectively; angiotensin II for AT2R and AT1 R) in the PRESTO-Tango system. HTLA cells were transfected and stimulated as in Fig. 4. Data are mean ± range of technical replicates; representative of 3 independent experiments. EC50 values were determined by nonlinear regression (4-parameter logistic fit). EC50(68W on B2R) = 500 nM; EC50 (BK on B2R) = 100 nM.

[0030] FIG. 6. Assays of B1 R (BDKRB1) activation or inhibition by CXCL14 peptides: SEQ ID NO:8, 68W and SEQ ID NO:12, 61 F inhibit B1 R (PRESTO-TANGO system). LEFT: Overnight treatment with indicated peptides at 3pM failed to activate B1 R (P value vsB1 R alone >0.4). RIGHT: Peptides 68W and 61 F applied 15 minutes (37 °C) prior to equimolar concentrations of DesArg BK or BK blocked B1 R activation by BK or desArgBK. Data normalized to the response to desArgBK (2 experiments) or to BK (1 experiment): presented as mean of the three independent experiments with SEM. P values (inhibition assay) for comparison to BK or desArgBK, one-way ANOVA followed by Tukey’s multiple comparisons post hoc test.

[0031] FIG. 7. Schematic of the hypothesized role of CXCL14 (X14) in vascular protection. Data to date shows that SEQ ID NO:8, X14 68W activates the protective GPCRs B2R and AT2R, and that SEQ ID NO:8, 68W and SEQ ID NO:12, 61 F inhibit B1R. This unique polypharmacology shows a primary vasoprotective role for X14.

[0032] FIGS. 8A-8D. Calcium flux, NFAT luciferase reporter and binding assays. (A) Calcium flux B2R signaling assay: peptide survey. CHO cells stably expressing HA-tagged (N- terminus) human B2R (BDKRB2) and loaded with calcium-sensitive fluorescent dye (BD Biosciences PBX Calcium Assay Kit, cat# 640175 for twenty minutes at 37°C) were stimulated with the indicated CXCL14 peptides (each at 1 pM). SEQ ID NO:8, 68W showed highest signal, relative to the maximal response induced by Bradykinin. Data normalized to baseline fluorescence are presented with mean ± SEM of 3 technical replicates; representative of 2 independent experiments. (B) Kinetics of calcium mobilization. CHO-B2R cells were loaded with calcium dye as in (A) and stimulated with 1 pM SEQ ID NO:8, 68W, 1 pM bradykinin (positive control) or vehicle. Baseline fluorescence was measured before ligand addition (Fo). Data were normalized as in (A). Mean ± SEM, with n = 3 technical replicates, representative of 3 independent experiments (C) NFAT reporter assay shows B2R activation by 68W, CXCL14 68W and human IgG Fc CXCL14 68W (lgG-Fc-CXCL14_68W). CHO-B2R cells carrying an NFAT-luciferase reporter (Promega, cat# E8481) were stimulated with SEQ ID NO:8, 68W peptide (500nm, 2.5 pM and 12.5 pM), synthetic fluorescent CXCL14 chemokine terminating at 68W (FAM CXCL14 68W) or human IgG Fc-CXCL14 68W (0.6 nM and 1 ,25nM) for 6 hours. Luciferase activity was measured and normalized to vehicle control. Data are mean ± SEM from 3 independent experiments, each with 3 technical replicates. *P < 0.05, **P < 0.01, ***P < 0.001 ; 1-way ANOVA with Tukey’s multiple comparison test. Comparison groups: 68W and CXCL14 68W were compared to vehicle-treated B2R-expressing cells; lgG-Fc_CXCL14_68W was compared to supernatants from non-transfected control cells. (D) Competitive binding assay. CHO- B2R cells were incubated for 10-minute on ice with 3 nM-300 nM of unlabeled IgG Fc- CXCL14 68W (the competitor) prior to addition of 300 nM FAM-labeled CXCL14 68W(the ‘tracer’) on ice. 30 min later, cells were washed and binding was measured by flow cytometry (Cytek Aurora). IC50 = 20 nM Data are mean ± SEM of 3 technical replicates. Representative of 2 independent experiments.

[0033] FIGS. 9A-9F. Alphafold models suggest a structural basis for CXCL14 interaction with B2R (encoded by BKRB2) and AT2R(AGTR2). (A-B); Overall architecture of the complex between BKRB2 and CXCL14 68W (SEQ ID NO: 33). In (A), the receptor is shown as a cut-away electrostatic mesh and the chemokine in black ribbon; C-terminal residues of the chemokine are shown as sticks. In (B), the chemokine is shown as an electrostatic mesh and the receptor as a white ribbon, interacting polar residues are shown as sticks and the ‘toggle-switch’ tryptophan (BW 6.48) as spheres. (C) Overlay of the binding pose of the truncated CXCL14 C-terminus (black) with T-kinin (green), in the orthosteric binding pocket of BKRB2. Selected aromatic residues of both peptides are shown as sticks. (D) Polar interactions between CXCL14 68W residues 60-68 and the orthosteric binding pocket of BKRB2. Complex is viewed perpendicular to the plane of the membrane from the extracellular side. Cyan dotted lines are hydrogen bonds. (E) Overlay of the binding pose of the CXCL14_68W C-terminus (black) with Angll (magenta), in the orthosteric binding pocket of AGTR2, aromatic residues of both peptides are shown as sticks. (E-F) Cut-away of the AGTR2 binding pocket, colored by electrostatic potential, with the ligand C-terminus (aa 61-68).

[0034] FIG. 10. Scoring of CXCL14 peptide pairing with receptors in silica. The distribution of inverse RTCNN scores (higher number means more favorable interaction) for AF3 models of receptor complexes with 8AA peptides from the C-terminus of CXCL14, terminating with residues 60R through 73R (enumerated within the mature sequence NO: 1). Peptides (see Table 1 for sequences) modeled with acceptable scores are labeled. Peptide SEQ ID NO:8, 68W is highlighted. Peptide 68W shows as the best binder for BKRB1 and BKRB2 and second best for AGTR2; its score for AGTR1 is very poor. Several peptides have excellent scores and are predicted to bind, including SEQ ID NO:12, 61 F with B1 R and AT1 R (but not B2R or AT2R), SEQ ID NO:13, 62I for AT2R, and multiple peptides for AT1 R.

[0035] FIGS. 11 A-11 C. T ransient B2R-dependent vascular leakage induced by active CXCL14 peptides. A. Photographs: Active peptide SEQ ID NO:8, 68W induces vascular leakage inhibited by the B2R selective antagonist icatibant (HOE 140). Shorter C term peptide SEQ ID NO:12, 61 F and full length mature CXCL14 were less active or inactive. Representative images of 3 mouse experiments. Anesthetized mice were injected iv with 0.1 ml of 1% (w / v) Evans blue dye (±2.5pg icatibant). Twenty minutes later, 50 pl of peptide (100 pM) or saline was injected intradermally. Animals were sacrificed 10 min later. B. Quantification by image-based morphometric analysis (ImageJ). Leakagearea is expressed in mm2. Data are presented as mean ± s.e.m. from three independent experiments *P< 0.05, **P< 0.01, ***p< 0.001 ; one-way ANOVA with Tukey’s multiple comparisons test. C. 68W induces vascular leakage independently of endogenous Bradykinin. The Miles assay was performed in Kng1~ / ~-, Kng2~ / ~ double-knockout (bradykinin-deficient) female mice (12-15 weeks old). Protocol as in (A), n = 6 mice. Data are presented as mean ± s.e.m. **P < 0.01 ; ***P < 0.001 ; one-way ANOVA with Tukey’s multiple comparisons test.

[0036] FIG. 12. Blood pressure (BP) regulation by CXCL14 peptides. Mice were acclimatized to the restrainer for 2 days before baseline measurements and BP monitored by CODA automated tail-cuff system (Kent Scientific). LEFT: Short term B2R-dependent BP reduction by unmodified peptide 68W. 10-12-week-old male C57BL / 6J mice (n = 3-4 mice / group) received subcutaneous (s.c.) injection of 100 pg of 61 F (control peptide), 68W, bradykinin (BK), or 68W plus icatibant (100 pg of each). Blood pressure and heart rate were monitored at 5-minute intervals beginning 15 minutes post-injection for 30 minutes. Peptide 68W produces approximately 20-30-minute systolic BP reduction, blocked by icatibant. CENTER: BP monitored after a single subcutaneous injection of palmitoylated peptides (s.c.): each of palm-68W (150 pg) and an equimolar amount of palm-77E induce sustained 24-hour BP suppression. In contrast, mutant peptide palm- 77E_W68A (SEQ ID NO: 36) is inactive. N = 5-8 mice / group. 68W and 77E groups showed a significant reduction in systolic BP at the 6 and 24 hour timepoints (P<0.01 , 2 way ANOVA), and 68W showed significant decrease for diastolic BP at 3, 6 and 24 hour timepoints (P < 0.05, P < 0.01, P < 0.01). The effect of 77E was delayed: both systolic and diastolic BP were not significantly changed in the palm77E group at the 3 hour timepoint, consistent with the requirement that 77E (as a proform) be activated by endogenous proteases. RIGHT: Chronic Ang II hypertension model. Fifteen-week-old male C57BL / 6J mice received angiotensin II (Ang II, 1.5 mg / kg / day) via subcutaneous osmotic minipump (Alzet model 2004) and were treated with daily subcutaneous palm- 68W or palm-77E (300 pg / day, n = 3-5 mice / group) or vehicle (n = 4) for 4 weeks. BP measured one day prior to and 1 , 3, 7, 14, 21 and 28 days following Ang II infusion. Both palm-68W and palm-77E normalize BP, countering the hypertensive effect of Angll.

[0037] FIGS. 13A-13C. (A) Predicted chymotryptic cleavage sites in the C terminal alpha helical domain of CXCL14, SEQ ID NO:1 residues 54-77 (residues 76-99 of the Uniprot protein with signal peptide). Expasy peptide cutter high probability sites shown with arrows and predicted consequences. The active peptide 68W is underlined. (B) LC- ESI-MS peak from analysis of chymase-treated CXCL14 peptide “short 70E”, SEQ ID NO:19 (FIKWYNAWNE). Presence of peptide FIKWYNAW after protease treatmentsupports chymase cleavage at activating tryptophan 68W. The base peak at 62.6 min retention time has a mass / charge ratio (m / z) = 564.287 Da, corresponding to half the predicted mass of the doubly-charged (z=2) protonated (M+H) peptide SEQ ID NO:19, residues 1 -8, FIKWYNAW: 1 ,127.549 Da. Overlapping peaks at the same retention time reflect different ionization states of the peptide. (C) Summary of predicted cleavage sites actually observed in the spectra of chymase and ECE1 products of short 70E.

[0038] FIGS. 14A-14B. (A) Chymotryptic proteases generate B2R-active fragments from CXCL14. Transfected KLK7 cleaves co-transfected CXCL14 FL to yield BDKRB2- activating product. B2R NFAT reporter activation by conditioned media. CHO cells were plated in 24 well plates at ~7 x 104cells / well and co-transfected with full length CXCL14 expression construct and either active human KLK7, catalytically inactive mutant KLK7(H57A / D102N / S195A triple mutant), or active human mast cell chymase (CMA1) expression constructs. After 48 hours post transfection, conditioned media were collected and transferred to B2R- CHO NFAT reporter cells. Luciferase activity was measured after 6-hour incubation and normalized to vehicle control. Data are mean ± SEM of 3-6 replicates from 3 independent experiments. ***P < 0.0005,* ****P<0.0001 ; 2-way ANOVA with Sidak's multiple comparisons test. Comparison groups: active KLK7 vs inactive KLK7, chymase and KLK7 co-transfected with full length CXCL14 vs vehicle control. (B) Kallikrein-related peptidase 7 (KLK7) induced vascular leakage: Intradermal KLK7 induces vascular leakage that is suppressed by systemic B2R inhibitor, icatibant. Control treatment represents relevant enzyme activation buffer. The data is presented as mean ± SEM and is representative of four independent experiments for the untreated group, and two independent experiments for the Icatibant-treated group. Statistical significance was assessed using an unpaired one-tailed t-test (a directional test was used because B2R inhibition is predicted to suppress, not enhance, KLK7-induced leakage); P < 0.05 compared to control treatment.

[0039] FIG. 15. Effects of CXCI14 peptides on Angll-induced cardiac dysfunction:Transthoracic echocardiography was performed in 15-week-old male C57BL / 6 mice after 4-week Ang II infusion (1.5 mg / kg / day delivered via subcutaneous osmotic minipump, Alzet model 2004) with daily subcutaneous injection of palm-77E, palm-68W (both 300 pg / day) or an equal volume of vehicle control. Groups: Ang II + vehicle (n = 4), Ang II + palm-68W, Ang II + palm-77E (n = 5), and no-Ang II infusion controls (n = 5). Left: ejection fraction (EF, %); right: fractional shortening (FS, %), calculated from M-mode parasternal short-axis images at the mid-papillary / mid-ventricular level. Echocardiography performed on a Vevo 2100 Imaging System with a 40 MHz transducer under 2% isoflurane anesthesia. In histological analyses, more elongated myoblasts (smooth alpha-actin-positive) and capillary vessels (CD31 -positive) wereseen in the heart frozen sections of palm-77E- as compared vehicle- or palm-68W- treated mice (not shown). Two-tailed Student’s T-test, P < 0.05 and P < 0.01 between two groups. 77E-treated versus no-Ang II controls: NS for both EF (P = 0.6405) and FS (P = 0.5092), indicating full cardioprotection.

[0040] FIGS. 16A-16H. Effect of CXCL14 peptide 77E on abdominal aortic aneurysm formation. Experimental AAAs were induced in 10-weeks-old WT male C57BL / 6J mice via topical application of porcine pancreatic elastase to surgically exposed intrarenal aorta (45 units / ml, 7.5 pl for 5 minutes; n = 6 mice per group). Mice were treated with peptide 77E (300 ug / mouse / day via subcutaneous injection) or an equal volume of vehicle starting one day prior to AAA induction for a total of 14 days. Aneurysm formation and progression was monitored via serial measurements of intrarenal aortic luminal diameters on the Vevo 2100 Imaging System. Fourteen days after AAA creation, mice were euthanized, and aortic frozen sections were prepared for immunohistopathological assessments. Medial elastin degradation, smooth muscle cell (SMC) alpha actin-positive SMC loss and aortic CD68-positive macrophage accumulation were scored as grade I (mild) to IV (severe). Subsets of individual lymphocytes and neoangiogenesis were quantitated as subset-specific antibody positively stained cells or vessels per aortic cross-section (ACS). (A): Quantitation of intrarenal aortic diameters (mean and SEM) at the baseline and indicated days following AAA induction. Two-way repeated-measures ANOVA with Sfdak multiple comparison post-hoc test, P < 0.01 compared to vehicle treatment at same time point. (B, C): Semiquantitation of elastin degradation and SMC loss (median and interquartile (25thand 75th)). Non-parametric Mann-Whitney, P > 0.999 for elastin and P = 0.3723 for SMC loss between two groups. (D): Semi-quantitation of aortic CD68-positive macrophage accumulation (median and interquartile (25thand 75th). Non-parametric Mann-Whitney, *P < 0.05 compared to vehicle treatment. (E-G): Quantitation of individual subsets of lymphocytes (CD4+T cells, CD8+T cells and B220+B cells; mean ± SEM) per ACS. Student’s T-test, *P < 0.05 and **P < 0.01 for CD4+T cells and B220+B cells, respectively, compared to vehicle treatment. (H): Quantitation of CD31 -positive neovessels per ACS. Student’s T-test, **P < 0.01 compared to vehicle treatment.

[0041] FIG. 17. Active peptide 68W (but not pro-peptide 77E) induces local irritation at SQ injection site. Adult male C57BL / 6 mice (12 weeks old) received intradermal injections of 68W (100 pM in 50 pL saline) or 77E (equimolar) on one flank, with saline injected on the contralateral side as an internal control. Mice were individually placed in clear observation chambers and video-recorded for 20 min. Local irritation scoring: Scratch bouts (defined as repetitive hindlimb scratching movements directed toward the injection site) were manually quantified from video recordings by a blinded observer.Data are presented as mean ± s.e.m.; n = 4 total (two mice per condition per experiment, two independent experiments). P< 0.05, one way ANOVA followed by Tukey's multiple comparisons test (68W vs 77E).DETAILED DESCRIPTION

[0042] Before the present methods and compositions are described, it is to be understood that this invention is not limited to particular method or composition described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0043] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0044] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some potential and preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. It is understood that the present disclosure supercedes any disclosure of an incorporated publication to the extent there is a contradiction.

[0045] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and reference to "the peptide" includes reference to one or more peptides and equivalents thereof, e.g. polypeptides, known to those skilled in the art, and so forth.

[0046] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admissionthat the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

[0047] As used herein, compounds which are "commercially available" may be obtained from commercial sources including but not limited to Acros Organics (Pittsburgh PA), Aldrich Chemical (Milwaukee Wl, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park UK), Avocado Research (Lancashire U.K.), BDH Inc. (Toronto, Canada), Bionet (Cornwall, U.K.), Chemservice Inc. (West Chester PA), Crescent Chemical Co. (Hauppauge NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester NY), Fisher Scientific Co. (Pittsburgh PA), Fisons Chemicals (Leicestershire UK), Frontier Scientific (Logan UT), ICN Biomedicals, Inc. (Costa Mesa CA), Key Organics (Cornwall U.K.), Lancaster Synthesis (Windham NH), Maybridge Chemical Co. Ltd. (Cornwall U.K.), Parish Chemical Co. (Orem UT), Pfaltz & Bauer, Inc. (Waterbury CN), Polyorganix (Houston TX), Pierce Chemical Co. (Rockford IL), Riedel de Haen AG (Hannover, Germany), Spectrum Quality Product, Inc. (New Brunswick, NJ), TCI America (Portland OR), Trans World Chemicals, Inc. (Rockville MD), Wako Chemicals USA, Inc. (Richmond VA), Novabiochem and Argonaut Technology.

[0048] Compounds can also be made by methods known to one of ordinary skill in the art. As used herein, "methods known to one of ordinary skill in the art" may be identified though various reference books and databases. Suitable reference books and treatises that detail the synthesis of reactants useful in the preparation of compounds of the present invention, or provide references to articles that describe the preparation, include for example, "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; S. R. Sandler et al., "Organic Functional Group Preparations," 2nd Ed., Academic Press, New York, 1983; H. O. House, "Modern Synthetic Reactions", 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif. 1972; T. L. Gilchrist, “Heterocyclic Chemistry”, 2nd Ed., John Wiley & Sons, New York, 1992; J. March, “Advanced Organic Chemistry: Reactions, Mechanisms and Structure”, 4th Ed., Wiley-lnterscience, New York, 1992. Specific and analogous reactants may also be identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (the American Chemical Society, Washington, D.C., may be contacted for more details). Chemicals that are known but not commercially available in catalogs may be prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g., those listed above) provide custom synthesis services.

[0049] "Comparable cell" shall mean a cell whose type is identical to that of another cell to which it is compared. Examples of comparable cells are cells from the same cell line.

[0050] "Inhibiting" the onset of a disorder shall mean either lessening the likelihood of the disorder's onset, or preventing the onset of the disorder entirely. In the preferred embodiment, inhibiting the onset of a disorder means preventing its onset entirely.

[0051] "Treating" a disorder shall mean slowing, stopping or reversing the disorder's progression. In the preferred embodiment, treating a disorder means reversing the disorder's progression, ideally to the point of eliminating the disorder itself. As used herein, ameliorating a disorder and treating a disorder are equivalent.

[0052] "Inhibiting" the expression of a gene in a cell shall mean either lessening the degree to which the gene is expressed, or preventing such expression entirely. "Specifically inhibit" the expression of a protein shall mean to inhibit that protein's expression (a) more than the expression of any other protein, or (b) more than the expression of all but 10 or fewer other proteins.

[0053] "Antibody" shall include, by way of example, both naturally occurring and non-naturally occurring antibodies. Specifically, this term includes polyclonal and monoclonal antibodies, and fragments thereof. Furthermore, this term includes chimeric antibodies and wholly synthetic antibodies, and fragments thereof.

[0054] An antibody that “specifically binds to” or is “specific for” a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope without substantially binding to any other polypeptide or polypeptide epitope. In some embodiments, an antibody of the present disclosure specifically binds to a human CXCL14 peptide with a dissociation constant (Kd) equal to or lower than 100 nM, optionally lower than 10 nM, optionally lower than 1 nM, optionally lower than 0.5 nM, optionally lower than 0.1 nM, optionally lower than 0.01 nM, or optionally lower than 0.005 nM; in the form of monoclonal antibody, scFv, Fab, or other form of antibody measured at a temperature of about 4° C., 25° C., 37° C. or 42° C. Binding affinity can be measured by any method known in the art and can be expressed as, for example, on-rate, off-rate, dissociation constant (Kd), equilibrium constant (Keq) or any term in the art. Various examples of such affinity-matured antibodies are within the scope of the invention.

[0055] Antibodies of interest may specifically bind to a peptide of the disclosure. For example, in various embodiments, therapeutic antibodies for administration are characterized as binding to one or more processing sites (e.g., sites of proteolytic cleavage) in a human CXCL14 peptide, thereby effectively blocking processing of the propeptide to the active enzyme.

[0056] "Anti-sense nucleic acid" shall mean any nucleic acid which, when introduced into a cell, specifically hybridizes to at least a portion of an mRNA in the cell encoding a protein("target protein") whose expression is to be inhibited, and thereby inhibits the target protein's expression.

[0057] "Specifically hybridize" to a nucleic acid shall mean, with respect to a first nucleic acid, that the first nucleic acid hybridizes to a second nucleic acid with greater affinity than to any other nucleic acid.

[0058] "Subject" or "patient" shall mean any animal, such as a human, non-human primate, mouse, rat, guinea pig or rabbit.

[0059] "Suitable conditions" shall have a meaning dependent on the context in which this term is used. That is, when used in connection with an antibody, the term shall mean conditions that permit an antibody to bind to its corresponding antigen. When this term is used in connection with nucleic acid hybridization, the term shall mean conditions that permit a nucleic acid of at least 15 nucleotides in length to hybridize to a nucleic acid having a sequence complementary thereto. When used in connection with contacting an agent to a cell, this term shall mean conditions that permit an agent capable of doing so to enter a cell and perform its intended function. In one embodiment, the term "suitable conditions" as used herein means physiological conditions.CXCL14 Compositions

[0060] Chemokines are defined by their primary amino acid sequence and the arrangement of specific structurally important cysteine residues within the mature protein. These form disulfide bonds that maintain the structure of the chemokine monomer, which consists of a central three stranded -sheet, an overlying C-terminal a-helix, and a short unstructured N terminus that plays a critical role in receptor activation. Variation in the precise configuration of the two cysteines closest to the N terminus allows chemokines to be split into four subfamilies: CC, CXC, CX3C, and XC. In CC chemokines, these cysteines are directly juxtaposed, while CXC chemokines have a single variable amino acid between them. The sole CX3C chemokine has three amino acids between these two cysteines, while XC chemokines, of which there are two forms in humans and one in mice, lack the first and the third cysteines of the motif.

[0061] While chemokines are active as monomers, they also form homodimers, heterodimers, and higher order aggregates that can contain one or more chemokine species, and this can be influenced by interactions with GAGs. The full chemokine ‘interactome’ reveals complex and extensive interactions. Chemokines are also profoundly affected by post- translational modifications such as citrullination, nitration / nitrosylation, and cleavage by matrix metalloproteinases (MMPs), cathepsins, thrombin, plasmin, elastase, thedipeptidyl peptidase CD26, and other proteases. These changes can substantially modify chemokine activity.

[0062] Proteases are key chemokine regulators. For example, CD26-mediated trimming of two amino acids off a chemokine's N terminus can, depending on the chemokine, change receptor specificity, substantially alter receptor affinity or convert agonists into antagonists. Many MMPs can also modify this part of certain chemokines, and the impact of these modifications depends on the identity of the chemokine being studied. Proteases are also thought to help create and modify interstitial chemokine gradients, and have the capacity to degrade chemokines, or the ECM to which they are bound, so are important in regulating chemokine half-life and distribution.

[0063] Chemokine (C-X-C motif) ligand 14 (CXCL14) is a small cytokine belonging to the CXC chemokine family that is also known as BRAK (for breast and kidney-expressed chemokine). Mature CXCL14 has many of the conserved features of the CXC chemokine subfamily but has some differences too, such as a shorter N-terminus and five extra amino acids in the region between its third and fourth cysteines. CXCL14 is constitutively expressed at high levels in many normal tissues, where its cellular source is thought to be fibroblasts. This chemokine is reportedly chemotactic for monocytes and can activate these cells in the presence of prostag landin-E2 (PGE2). It is also reported to be a potent chemoattractant and activator of dendritic cells, is implicated in homing of these cells, and can stimulate the migration of activated NK cells. The gene for CXCL14 contains four exons and is located on chromosome 5 in humans. The refseq for the human gene may be found at Genbank, NM 004887.

[0064] The sequence of the CXCL14 precursor protein (SEQ ID NO:1) is MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVII TTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRRVYEE. The mature chemokine consists of residues 23-99, and various truncated C-terminal peptides are of interest as disclosed herein. The genetic sequence of the human gene is as follows (SEQ ID NO:2):gtggagagag cgcggagaca agcgcagagc gcagcgcacg gccacagaca gccctgggcat ccaccgacg gcgcagccgg agccagcaga gccggaaggc gcgccccggg cagagaaagc cgagcagagc tgggtggcgt ctccgggccg ccgctccgac gggccagcgc cctccccatg tccctgctcc cacgccgcgc ccctccggtc agcatgaggc tcctggcggc cgcgctgctc ctgctgctgc tggcgctgta caccgcgcgt gtggacgggt ccaaatgcaa gtgctcccgg aagggaccca agatccgcta cagcgacgtg aagaagctgg aaatgaagcc aaagtacccg cactgcgagg agaagatggt tatcatcacc accaagagcg tgtccaggta ccgaggtcag gagcactgcc tgcaccccaa gctgcagagc accaagcgct tcatcaagtg gtacaacgcc tggaacgaga agcgcagggt ctacgaagaa tagggtgaaa aacctcagaa gggaaaactc caaaccagtt gggagacttg tgcaaaggac tttgcagatt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaagcctttc tttctcacag gcataagaca caaattatat attgttatga agcacttttt accaacggtc agtttttaca ttttatagct gcgtgcgaaa ggcttccaga tgggagaccc atctctcttg tgctccagac ttcatcacag gctgcttttt atcaaaaagg ggaaaactca tgcctttcct ttttaaaaaa tgcttttttg tatttgtcca tacgtcacta tacatctgag ctttataagc gcccgggagg aacaatgagcttggtggaca catttcattg cagtgttgct ccattcctag cttgggaagc ttccgcttag aggtcctggc gcctcggcac agctgccacg ggctctcctg ggcttatggc cggtcacagc ctcagtgtga ctccacagtg gcccctgtag ccgggcaagc aggagcaggt ctctctgcat ctgttctctg aggaactcaa gtttggttgc cagaaaaatg tgcttcattc ccccctggtt aatttttaca caccctagga aacatttcca agatcctgtg atggcgagac aaatgatcct taaagaaggt gtggggtctt tcccaacctg aggatttctg aaaggttcac aggttcaata tttaatgctt cagaagcatg tgaggttccc aacactgtca gcaaaaacct taggagaaaa cttaaaaata tatgaataca tgcgcaatac acagctacag acacacattc tgttgacaag ggaaaacctt caaagcatgt ttctttccct caccacaaca gaacatgcag tactaaagca atatatttgt gattccccat gtaattcttc aatgttaaac agtgcagtcc tctttcgaaa gctaagatga ccatgcgccc tttcctctgt acatataccc ttaagaacgc cccctccaca cactgccccc cagtatatgc cgcattgtac tgctgtgtta tatgctatgt acatgtcaga aaccattagc attgcatgca ggtttcatat tctttctaag atggaaagta ataaaatata tttgaaatgt accaaaa

[0065] Peptides of interest for use in the methods of the disclosure as BDKRB2 activating agents may be from about 8 to about 68 amino acids in length, from about 8 to about 24 amino acids, from about 8 to about 16 amino acids, from about 8 to about 15 amino acids, and comprise at least a portion of the C-terminal region of SEQ I D NO:1 . Peptides may lack the inhibitory terminal sequence of CXCL14, SEQ ID NO:37, NEKRRVYEE. For example, a peptide may comprise at least the amino acid sequence SEQ ID NQ:40 WYNAW; or SEQ ID NO:12; or SEQ ID NO:8, and can lack the inhibitory amino terminus.

[0066] In some embodiments, an activated peptide comprises or consists of SEQ ID NO:33, i.e. the mature form of CXCL14, truncated to remove the inhibitory amino terminus. In other embodiments an activated peptide consists or comprises a sequence corresponding to SEQ ID NO:1 residues 72-90, residues 73-90, residues 74-90, residues 75-90. An activated peptide of particular interest consists or comprises SEQ ID NO:8, KLQSTKRFIKWYNAW. Active peptides also include shorter variants of this sequence, e.g. SEQ ID NO:12, 13, 32, 14, 15, 16, 17, 18, 19, 20, or 21.

[0067] In other embodiments a peptide of interest as a BDKRB2 activating agents is activated by cleavage in vitro or in vivo. Exemplary of this class of peptides is KLQSTKRFIKWYNAWNEKRRVYEE (SEQ ID NO:11) and other peptides that comprise all or a portion of the amino terminal region, e.g. SEQ ID NO:23-31. Such peptides may comprise or consist of, for example, SEQ ID NO:1 residues 72-99, residues 73-99, residues 74-99, residues 75-99, and may additional be truncated at the amino terminus, e.g. by 1 , 2, 3, 4, 5, 6, 7 or 8 amino acids. In some embodiments a modified version comprises or consists of the amino acid sequence of SEQ ID NO:36.

[0068] Certain peptides of interest are set forth in Table 1 , for example the truncated peptides:CXCL14 68W; SEQ ID NO:32 KLQSTKRFIK (referred to herein as peptide 63K); SEQ ID NO:9 KLQSTKRFIKWYNAWNE (referred to as 70E); SEQ ID NO:12 KLQSTKRF (referred to as 61 F); SEQ ID NO:13 KLQSTKRFI (referred to as 62I); SEQ ID NO:14 KLQSTKRFIKW (referred to as 64W); SEQ ID NO:15 KLQSTKRFIKWY (referred to as 65Y); SEQ ID NO:16 KLQSTKRFIKWYN (referred to as 66N); SEQ ID NO:17KRFIKWYNA (referred to as short 67A); SEQ ID NO:18 RFIKWYNAW (referred to as 60R-68W); SEQ ID NO:19 FIKWYNAW (referred to as 61F-68W); SEQ ID NQ:20 KRFIKWYNAW (referred to Short-68W); SEQ ID NO:21 KLQSTKRFIKWYNAWN (referred to as 69N); SEQ ID NO:22 FIKWYNAWNE (referred to as short 70E); KLQSTKRFIKWYNAWNEKRRVYEE (referred to as 77E). The peptides may be fused or otherwise conjugated to other moieties, e.g. an IgG Fc fused to 68W (referred to as Fc68W); or labeled with a fluorescent moiety, e.g. FAM 68W.Table 1 : Test Agent and Signaling ResponsesTest agent Signaling Responses CXCL14 with C term truncations: Tango coB2R B1R AT2R AT1R transfection (expressed from vectors)SEQ ID NO:1 residues 23-99 CXCL14_FL (full lengthwithout signal peptide)SKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVIITTK SVSRYRGQEHCLHPKLQSTKRFIKWYNAW NEKRRVYEE SEQ ID NO:33 CXCL14_68W ++++ - ++++ - SKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVIITTK SVSRYRGQEHCLHPKLQSTKRFIKWYNAW CXCL14_63K SEQ ID NO:34 - - - NT SKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVHTTK SVSRYRGQEHCLHPKLQSTKRFIK CXCL14_70E SEQ ID NO:35 - - - - SKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVIITTK SVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEBradykinin (RPPGFSPFR) SEQ ID NO:38 ++ NT NT Angiotensin (DRVYIHPF) SEQ ID NO:39 NT NT ++++++++ ++++++++ Synthetic Peptides from CXCL14 C term (designationsin parentheses)SEQ ID NO:8 KLQSTKRFIKWYNAW (68W) - +++++++ - SEQ ID NO:11 KLQSTKRFIKWYNAWNEKRRVYEE (77E) - - - - SEQ ID NO:9 KLQSTKR FIKWYNAWNE (70E) - - +++ - SEQ ID NO:10 KLQSTKRFIKWYNAWNEKRR NT NT NT NT SEQ ID NO:32 KLQSTKRFIK (63K) - ++ - SEQ ID NO:12 KLQSTKRF (61 F) - ++++ - SEQ ID NO:13 KLQSTKRFI (62I) - +++ - SEQ ID NO:14 KLQSTKRFIKW (64W) - +++ - SEQ ID NO:15 KLQSTKRFIKWY (65Y) - ++ - SEQ ID NO:16 KLQSTKRFIKWYN (66N) ++++ - + - SEQ ID NO:17 KRFIKWYNA (short 67A) + - ++++ - SEQ ID NO:18 RFIKWYNAW (60R-68W) + - + - SEQ ID NO:19 FIKWYNAW (61 F-68W) ++ - + - SEQ ID NQ:20 KRFIKWYNAW (Short-68W) ++ - ++ - SEQ ID NO:21 KLQSTKRFIKWYNAWN (69N) +++ - +++ +SEQ ID NO:22 FIKWYNAWNE (short 70E) - - + -IgG Fc and synthetic X14 68W (with chemokinedomain)human lgG_Fc_CXCL14_68W (Fc_CXCL14_68W) +++++++ - +++++++ - Fluorescent CXCL14 chemokine terminating at 68W +++++++ - + 4-4-4-+++ - (FAM_CXCL14_68W SEQ ID NO:33)Modified 68W peptidesFAM-KLQSTKRFIKWYNAW (FAM-68W SEQ ID NO:8) ++++++ - ++++++ - Palmityl-KLQSTKRFIKWYNAW (palmitoyl_68W SEQ ID NT NT NT NT NO:8)Other peptidesSEQ ID NO:23 KLQSTKRFIKWYNAWKSEQ ID NO:24 KLQSTKRFIKWYNAWRSEQ ID NO:25 FIKWYNAWNEKRRVYEESEQ ID NO:26 FIKWYNAWNEKRRVYESEQ ID NO:27 FIKWYNAWNEKRRVSEQ ID NO:28 FIKWYNAWNEKRRSEQ ID NO:29 FIKWYNAWNEKRSEQ ID NO:30 FIKWYNAWNEKSEQ ID NO:31 FIKWYNAWNSEQ ID NO:37 NEKRRVYEEMutant peptide 77E (W68A)SEQ ID NO:36 KLQSTKRFIKWYNAANEKRRVYEE(77E_W68A)Activity of CXCL14 C-terminal truncation variants, synthetic peptides and recombinant constructs on B2R (BDKRB2), B1 R (BDKRB1), AT2R (AGTR2) and AT1 R (AGTR1), assessed by PRESTO-Tango 0-arrestin reporter assay in HTLA cells. All peptides were tested at 3 pM (unless otherwise indicated) following a 16-hour incubation period. Activity is scored semi-quantitatively relative to the maximal response of the cognate agonist (3 pM bradykinin for B2R and Bl R; 3 pM angiotensin II for AT2R and AT1 R): - = no activity above vehicle; + through ++++++++ = increasing responses. NT or blank = not tested. Each peptide was tested in 3 technical replicates per experiment across 3-7 independent experimental dates. Peptide sequences and C-terminal residue numbers are listed. Constructs include: synthetic peptides (>95% purity by HPLC), palmitoylated conjugates (palm-68W peptide, palm-77E peptide), FAM-68W (fluorescently labeled 68W peptide), IgG Fc-CXCL14_68W (recombinant fusion), and CXCL14 expression constructs (full-length CXCL14 and truncation mutants shown including CXCL14_68W). Truncation mutant CXCL14_68W was also synthesized with an N-terminal FAM (Phoenix peptide, Inc). Nomenclature: residues are numbered from the N-terminus of the mature 77 amino acid long CXCL14 chemokine (SEQ ID NO:1 residues 23-99), with position 1 corresponding to the first residue following cleavage of the signal peptide. Peptide truncates are named for the position and identity of their C-terminal residue; for example, "68W" denotes a peptide whose C-terminus is the tryptophan at position 68 of mature CXCL14.

[0069] In some embodiments a peptide comprises a partially re-processed or engineered precursor of active peptides, which peptides of interest include peptides comprising C terminal sequences of CXCL14 extending beyond tryptophan W68 (measured from the mature CXCL14 without the signal peptide) or peptides with modified C terminal sequences extending C terminal to W68. Examples include peptides terminating C terminally in SEQ ID NO:25 FIKWYNAWNEKRRVYEE, SEQ ID NO:26 FIKWYNAWNEKRRVYE, SEQ ID NO:27 FIKWYNAWNEKRRV, SEQ ID NO:28 FIKWYNAWNEKRR, SEQ ID NO:29 FIKWYNAWNEKR, SEQ ID NQ:30FIKWYNAWNEK, SEQ ID NO:22 FIKWYNAWNE or SEQ ID NO:31 FIKWYNAWN. Additional examples include peptides terminating C terminal to 68W in alternative amino acid sequences including peptides terminating in N (e.g. SEQ ID NO:21 KLQSTKRFIKWYNAWN), K (e.g. SEQ ID NO:23 KLQSTKRFIKWYNAWK) or R (e.g. SEQ ID NO:24 KLQSTKRFIKWYNAWR).

[0070] Various modifications may be made to the peptides, e.g. to increase the serum half-life, etc. In some embodiments a peptide is modified at the N-terminus, e.g. by engineering protection from DPP-4 enzyme by substitution of a natural amino acid at the second amino acid position from the terminus or at other positions with alpha-aminoisobutyric acid (Aib), (1-Nal) 1 -naphthylalanine, (2-thienyl)-Ala (Thi), methyl-tyrosine, ornithine, etc. Specific peptide modifications for half-life extension include amino acid substitutions, for example with D-enantiomers of amino acids, and non-natural amino acids. Aib may be substituted for alanine, serine, etc. Ornithine may be substituted for lysine. A reduced peptide bond can be inserted between two residues of interest, for example A67 and W68, between K and R, between R and F, etc.

[0071] In some embodiments peptides are conjugated to a fatty acid, e.g. on the N-terminus, or internal lysine residues. Fatty acids of interest include, without limitation, myristic acid, lauric acid, palmitic acid, stearic acid, octadecanedioic acid, hexadecanedioic acid, etc. The selection of fatty acids for peptide conjugation is driven by the need to balance hydrophobicity (to facilitate albumin binding) and solubility (to prevent peptide aggregation). The choice of chain length and the presence of terminal functional groups are the primary variables in drug design. The conjugate may utilize a standard fatty acids (monoacids), or a dicarboxylic acids (diacids), e.g. octadecanedioic acid, etc. Fatty acids may be attached via spacer / linker modules such as mini-PEG, OEG, y-Glu, etc. n some embodiments, for example, a fatty acid of from about C6 to about C20, e.g. C8, C10, C12, C14, C16, C18, etc. is linked to an amino group on the peptide, often a lysine residue. The fatty acid may be linked via a glutamic acid and two (2-(2- aminoethoxy)ethoxy)acetic acid units to the side chain of the lysine residue, which prolongs its duration of action.

[0072] Prenylation attaches isoprenoid lipids such as farnesyl, geranylgeranyl, etc. to cysteine residues. A GPI anchor attaches glycosylphosphatidylinositol to the C-terminus. Lipidation can also involve attaching cholesterol, phosphatidylethanolamine, or other lipids to the peptide.

[0073] The C-terminus of the peptide may also be modified, e.g. by amidation to increase biological activity and stability. Peptides can also be modified to incorporate a C- terminal extension, e.g. a "Trp-cage" derived from the Gila monster venom peptide,which provides significant protection against degradation. Modifications like acetylation (N-terminal), and methylation (N-terminal) can alter the peptide's charge and stability, potentially influencing its half-life.

[0074] In some embodiments, a polypeptide is conjugated to additional molecules to provide desired pharmacological properties such as extended half-life. In one embodiment, a polypeptide can be fused to the Fc domain of IgG, albumin, or other molecules to extend its half-life, e.g. by pegylation, glycosylation, and the like as known in the art. In some embodiments the polypeptide is conjugated to a polyethylene glycol molecules or “PEGylated.” The molecular weight of the PEG conjugated to the polypeptide ligand include but are not limited to PEGs having molecular weights between 5kDa and 80kDa, in some embodiments the PEG has a molecular weight of approximately 5kDa, in some embodiments the PEG has a molecular weight of approximately 10kDa, in some embodiments the PEG has a molecular weight of approximately 20kDa, in some embodiments the PEG has a molecular weight of approximately 30kDa, in some embodiments the PEG has a molecular weight of approximately 40kDa, in some embodiments the PEG has a molecular weight of approximately 50kDa, in some embodiments the PEG has a molecular weight of approximately 60kDa in some embodiments the PEG has a molecular weight of approximately 80kDa. In some embodiments, the molecular mass is from about 5kDato about 80kDa, from about 5kDa to about 60kDa, from about 5kDa to about 40kDa, from about 5kDa to about 20kDa. The PEG conjugated to the polypeptide sequence may be linear or branched. The PEG may be attached directly to the polypeptide, or attached via a linker molecule. The processes and chemical reactions necessary to achieve PEGylation of biological compounds is well known in the art.

[0075] The polypeptide can be acetylated at the N-terminus, using methods known in the art, e.g. by enzymatic reaction with N-terminal acetyltransferase and, for example, acetyl CoA. The polypeptide can be acetylated at one or more lysine residues, e.g. by enzymatic reaction with a lysine acetyltransferase. See, for example Choudhary et al. (2009). Science. 325 (5942): 834-840.

[0076] Fc-fusion can also endow alternative Fc receptor mediated properties in vivo. The "Fc region" can be a naturally occurring or synthetic polypeptide that is homologous to an IgG C-terminal domain produced by digestion of IgG with papain. IgG Fc has a molecular weight of approximately 50 kDa. The ortholog IL-2 polypeptides can include the entire Fc region, or a smaller portion that retains the ability to extend the circulating half- life of a chimeric polypeptide of which it is a part. In addition, full-length or fragmented Fc regions can be variants of the wild-type molecule. That is, they cancontain mutations that may or may not affect the function of the polypeptides; as described further below, native activity is not necessary or desired in all cases.

[0077] In other embodiments, a polypeptide can comprise a sequence that functions as an antigenic tag, such as a FLAG sequence. FLAG sequences are recognized by biotinylated, highly specific, anti-FLAG antibodies, as described herein (see also Blanar et al., Science 256: 1014, 1992; LeClair et al., Proc. Natl. Acad. Sci. USA 89:8145, 1992). In some embodiments, the chimeric polypeptide further comprises a C-terminal c-myc epitope tag.

[0078] As described above, the proteins of the invention may exist as a part of a chimeric polypeptide. In addition to, or in place of, the heterologous polypeptides described above, a nucleic acid molecule of the invention can contain sequences encoding a "marker" or "reporter." Examples of marker or reporter genes include p-lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo1 , G418r), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacz (encoding p- galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT). As with many of the standard procedures associated with the practice of the invention, skilled artisans will be aware of additional useful reagents, for example, of additional sequences that can serve the function of a marker or reporter.

[0079] The term "identity," as used herein in reference to polypeptide or DNA sequences, refers to the sequence identity between two molecules. The similarity between two amino acid or two nucleotide sequences is a direct function of the number of identical positions. In general, the sequences are aligned so that the highest order match is obtained. If necessary, identity can be calculated using published techniques and widely available computer programs, such as the GCS program package (Devereux et al., Nucleic Acids Res. 12:387, 1984), BLASTP, BLASTN, FASTA (Atschul et al., J. Molecular Biol. 215:403, 1990). Sequence identity can be measured using sequence analysis software such as the Sequence Analysis Software Package of the Genetics Computer Group at the University of Wisconsin Biotechnology Center (1710 University Avenue, Madison, Wis. 53705), with the default parameters thereof. A peptide useful in the methods of the disclosure may differ from a sequence provided herein by 1 amino acid, e.g. deletion or substitution of a residue, by 2 amino acids, by 3 amino acids, or more. The peptides may have 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity to the sequences disclosed herein.

[0080] By "protein variant" or "variant protein" or "variant polypeptide" herein is meant a protein that differs from a wild-type protein by virtue of at least one amino acid modification.The parent polypeptide may be a naturally occurring or wild-type (WT) polypeptide or may be a modified version of a WT polypeptide. The term variant polypeptide may refer to the polypeptide itself, a composition comprising the polypeptide, or the nucleic acid sequence that encodes it. Preferably, the variant polypeptide comprises at least one amino acid modification compared to the parent polypeptide, e.g. from about one to about ten amino acid modifications, and preferably from about one to about five amino acid modifications compared to the parent. A variant may be at least about 99% identical to the wild-type protein, at least about 98% identical, at least about 97% identical, at least about 95% identical, at least about 90% identical.

[0081] By "parent polypeptide", "parent protein", "precursor polypeptide", or "precursor protein" as used herein is meant an unmodified polypeptide that is subsequently modified to generate a variant polypeptide. A parent polypeptide may be a wild-type (or native) polypeptide. Parent polypeptide may refer to the polypeptide itself, compositions that comprise the parent polypeptide, or the amino acid sequence that encodes it.

[0082] By "wild type" or "WT" or "native" herein is meant an amino acid sequence or a nucleotide sequence that is found in nature, including allelic variations. A WT protein, polypeptide, antibody, immunoglobulin, IgG, etc. has an amino acid sequence or a nucleotide sequence that has not been modified by the hand of man.

[0083] Polypeptides may also include conservative modifications and substitutions at other positions of the chemokine. Such conservative substitutions include those described by Dayhoff in The Atlas of Protein Sequence and Structure 5 (1978), and by Argos in EMBO J., 8:779-785 (1989). For example, amino acids belonging to one of the following groups represent conservative changes: Group I: ala, pro, gly, gin, asn, ser, thr; Group II: cys, ser, tyr, thr; Group III: val, ile, leu, met, ala, phe; Group IV: lys, arg, his; Group V: phe, tyr, trp, his; and Group VI: asp, glu. In each instance, the introduction of additional modifications may be evaluated to minimize any increase in antigenicity of the modified polypeptide in the organism to which the modified polypeptide is to be administered.

[0084] Peptides may be formulated as pharmaceutical compositions for administration by parenteral routes (e.g., subcutaneous, intravenous, intraperitoneal, intramuscular, or transdermal). Such pharmaceutical compositions and processes for preparing same are well known in the art. (See, e.g., Remington: The Science and Practice of Pharmacy (D. B. Troy, Editor, 21st Edition, Lippincott, Williams & Wilkins, 2006).

[0085] The compounds of the present invention may react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Pharmaceutically acceptable salts and common methodology for preparing them are well known in the art. See, e.g., P. Stahl, et al. Handbook of Pharmaceutical Salts:Properties, Selection and Use, 2nd Revised Edition (Wiley-VCH, 2011); S. M. Berge, et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, Vol. 66, No. 1 , January 1977. Pharmaceutically acceptable salts of the present invention include trifluoroacetate, hydrochloride, and acetate salts.

[0086] Peptides, e.g. recombinantly produced peptides can be recovered from the culture medium or recovered from host cell lysates. A protease inhibitor, such as phenyl methyl sulfonyl fluoride (PMSF) also may be useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent the growth of adventitious contaminants. Various purification steps are known in the art and find use, e.g. affinity chromatography. Affinity chromatography makes use of the highly specific binding sites usually present in biological macromolecules, separating molecules on their ability to bind a particular ligand. Covalent bonds attach the ligand to an insoluble, porous support medium in a manner that overtly presents the ligand to the protein sample, thereby using natural biospecific binding of one molecular species to separate and purify a second species from a mixture. Antibodies are commonly used in affinity chromatography. Size selection steps may also be used, e.g. gel filtration chromatography (also known as size-exclusion chromatography or molecular sieve chromatography) is used to separate proteins according to their size. In gel filtration, a protein solution is passed through a column that is packed with semipermeable porous resin. The semipermeable resin has a range of pore sizes that determines the size of proteins that can be separated with the column. Also of interest is cation exchange chromatography.

[0087] The protein composition may be concentrated, filtered, dialyzed, etc., using methods known in the art. Administration may be intravenous, as a bolus or by continuous infusion over a period of time. Alternative routes of administration include intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes.

[0088] Such dosage forms encompass physiologically acceptable carriers that are inherently non-toxic and non-therapeutic. Examples of such carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, and PEG. Carriers for topical or gel-based forms of polypeptides include polysaccharides such as sodium carboxymethylcellulose ormethylcellulose, polyvinylpyrrolidone, polyacrylates, polyoxyethylene- polyoxypropylene-block polymers, PEG, and wood wax alcohols. For all administrations, conventional depot forms are suitably used. Such forms include, for example, microcapsules, nano-capsules, liposomes, plasters, inhalation forms, nose sprays, sublingual tablets, and sustained-release preparations. The peptides will typically be formulated in such vehicles at a concentration of about 0.1 pg / ml to 100 pg / ml.

[0089] In the event the polypeptides of the disclosure are "substantially pure," they can be at least about 60% by weight (dry weight) the polypeptide of interest, for example, a polypeptide containing the amino acid sequence. For example, the polypeptide can be at least about 75%, about 80%, about 85%, about 90%, about 95% or about 99%, by weight, the polypeptide of interest. Purity can be measured by any appropriate standard method, for example, column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

[0090] In another embodiment of the invention, an article of manufacture containing materials useful for the treatment of the conditions described above is provided. The article of manufacture comprises a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition that is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The label on, or associated with, the container indicates that the composition is used for treating the condition of choice. Further container(s) may be provided with the article of manufacture which may hold, for example, a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution or dextrose solution. The article of manufacture may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

[0091] Included in the compositions of the disclosure are polynucleotides encoding any of the polypeptide sequences disclosed herein Such polypeptides may be inserted into a replicable vector, e.g. for expression, genome integration and modification, etc. Many such vectors are available. The vector components generally include, but are not limited to, one or more of the following: an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Vectors include viral vectors, plasmid vectors, integrating vectors, and the like.

[0092] Expression may be viral vectors or non-viral vectors. Plasmids are examples of non- viral vectors. In order to facilitate transfection of the target cells, the target cell may be exposed directly with the non-viral vector may under conditions that facilitate uptake of the non-viral vector. Examples of conditions which facilitate uptake of foreign nucleic acid by mammalian cells are well known in the art and include but are not limited to chemical means (such as Lipofectamine®, Thermo-Fisher Scientific), high salt, and magnetic fields (electroporation).

[0093] In one embodiment, a non-viral vector may be provided in a non-viral delivery system.Non-viral delivery systems are typically complexes to facilitate transduction of the target cell with a nucleic acid cargo wherein the nucleic acid is complexed with agents such as cationic lipids (DOTAP, DOTMA), surfactants, biologicals (gelatin, chitosan), metals (gold, magnetic iron) and synthetic polymers (PLG, PEI, PAMAM). Numerous embodiments of non-viral delivery systems are well known in the art including lipidic vector systems (Lee et al. (1997) Grit Rev Ther Drug Carrier Syst. 14:173-206); polymer coated liposomes (Marin et al., U.S. Pat. No. 5,213,804, issued May 25, 1993; Woodie, et al., U.S. Pat. No. 5,013,556, issued May 7, 1991); cationic liposomes (Epand et al., U.S. Pat. No. 5,283,185, issued Feb. 1 , 1994; Jessee, J. A., U.S. Pat. No. 5,578,475, issued Nov. 26, 1996; Rose et al, U.S. Pat. No. 5,279,833, issued Jan. 18, 1994; Gebeyehu etal., U.S. Pat. No. 5,334,761 , issued Aug. 2, 1994).

[0094] In another embodiment, the expression vector may be a viral vector. Retroviral or lentiviral expression vectors may be used. In particular, the viral vector is a gamma retrovirus, self-inactivating lentiviral vectors, and retroviral vectors as described in Naldini, etal. (1996) Science 272: 263-267; Naldini, etal. (1996) Proc. Natl. Acad. Sci. USA Vol. 93, pp. 11382-11388; Dull, etal. (1998) J. Virology 72(11 ) :8463— 8471 ; Milone, et al. (2009) 17(8):1453-1464; Kingsman, et al. United States patent No 6,096,538 issued August 1 , 2000 and Kingsman, etal. United States patent No. 6,924,123 issued August 2, 2005.

[0095] Expression vectors usually contain a selection gene, also termed a selectable marker.This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media.

[0096] Expression vectors will contain a promoter that is recognized by the host organism and is operably linked to the protein coding sequence. Promoters are untranslated sequences located upstream (5') to the start codon of a structural gene (generally withinabout 100 to 1000 bp) that control the transcription and translation of particular nucleic acid sequence to which they are operably linked. Such promoters typically fall into two classes, inducible and constitutive. Inducible promoters are promoters that initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, e.g., the presence or absence of a nutrient or a change in temperature. A large number of promoters recognized by a variety of potential host cells are well known.

[0097] Transcription from vectors in mammalian host cells may be controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus (such as murine stem cell virus), hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter, PGK (phosphoglycerate kinase), or an immunoglobulin promoter, from heat-shock promoters, provided such promoters are compatible with the host cell systems. The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication.

[0098] Transcription by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, which act on a promoter to increase its transcription. Enhancers are relatively orientation and position independent, having been found 5' and 3' to the transcription unit, within an intron, as well as within the coding sequence itself. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, alpha- fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the expression vector at a position 5' or 3' to the coding sequence but is preferably located at a site 5' from the promoter.

[0099] Expression vectors used in eukaryotic host cells will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. Construction of suitable vectors containing one or more of the above-listed components employs standard techniques.

[0100] Suitable host cells for cloning or expressing the DNA in the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Examples of useful mammalian host cell lines are mouse L cells (L-M[TK-], ATCC#CRL-2648), monkeykidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture; baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cellsADHFR (CHO); mouse sertoli cells (TM4); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1 587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells; MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

[0101] Host cells can be transfected with the above-described expression vectors for expression. Cells may be cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. Mammalian host cells may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI 1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. Any of these media may be supplemented as necessary with hormones and / or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics, trace elements, and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

[0102] Nucleic acids are "operably linked" when placed into a functional relationship with another nucleic acid sequence. For example, DNA for a signal sequence is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous.Receptors

[0103] Angiotensin II receptor type 2 (AGTR2). Angiotensin II is an important effector controlling blood pressure and volume in the cardiovascular system. It acts through atleast two types of receptors termed AT1 and AT2. AGTR2 belongs to a family of G protein-coupled receptors. It is an integral membrane protein. It plays a role in the central nervous system and cardiovascular functions that are mediated by the reninangiotensin system. This receptor mediates programmed cell death (apoptosis). Consistent with its apoptotic function, angiotensin II receptor type II also opposes cell proliferation. The human AGTR2 gene is composed of three exons and spans at least 5 kb. Exons 1 and 2 encode for 5' untranslated mRNA sequence and exon 3 harbors the entire uninterrupted open reading frame. Stimulation of AT2 increases mucosal nitric oxide production. The human mRNA RefSeq (mRNA) may be accessed at NM 000686 or NM 001385624, and the protein refseq at NP 000677.

[0104] Angiotensin II receptor type 1 (AGTR1) is a Gq / 11-coupled G protein-coupled receptor (GPCR) and the best characterized angiotensin receptor. AT1 has vasopressor effects and regulates aldosterone secretion. It is an important effector controlling blood pressure and volume in the cardiovascular system. The AT1 receptor mediates the major cardiovascular effects of angiotensin II. Effects include vasoconstriction, aldosterone synthesis and secretion, increased vasopressin secretion, cardiac hypertrophy, augmentation of peripheral noradrenergic activity, vascular smooth muscle cells proliferation, decreased renal blood flow, renal renin inhibition, renal tubular sodium reuptake, modulation of central sympathetic nervous system activity, cardiac contractility, central osmocontrol and extracellular matrix formation.

[0105] Many polymorphisms have been reported for AGTR1 which provide an avenue to explore these polymorphisms for their implications in protein structure, function and drug efficacy. Angiotensin II receptor type 1 has been shown to interact with Zinc finger and BTB domain-containing protein 16.

[0014] The protein's mRNA has been reported to interact with Mir-132 microRNA as part of an RNA silencing mechanism that reduces receptor expression.

[0106] The human mRNA RefSeq (mRNA) may be accessed at NM_032049, NM_000685, NM 004835, NM_009585, and NM_031850, and the protein refseq at NP_000676, NP 004826, NP 033611 , NP_114038, and NP_114438.

[0107] Bradykinin receptor B2. The B2 receptor (B2R) is a G protein-coupled receptor, probably coupled to Gq and Gi. The B2 receptor forms a complex with angiotensin converting enzyme (ACE), and this is thought to play a role in cross-talk between the renin-angiotensin system (RAS) and the kinin— kallikrein system (KKS). The heptapeptide angiotensin also potentiates bradykinin action on B2 receptors. The 9 amino acid bradykinin peptide elicits several responses including vasodilation, edema, smooth muscle spasm and nociceptor stimulation. The human mRNA RefSeq (mRNA)may be accessed at NM 000623, and NM 001379692, and the protein refseq at NP 000614 and NP_001366621.

[0108] Bradykinin receptor B1 (B1) is a G-protein coupled receptor encoded by the BDKRB1 gene in humans. Its principal ligand is bradykinin, a 9 amino acid peptide generated in pathophysiologic conditions such as inflammation, trauma, burns, shock, and allergy. The B1 receptor is one of two of G protein-coupled receptors that have been found which bind bradykinin and mediate responses to these pathophysiologic conditions. Classical agonist of this receptor includes bradykininl -8 (bradykinin with the first 8 amino acid) and antagonist includes [Leu8]-bradykinin1-8.

[0109] The human mRNA RefSeq (mRNA) may be accessed at NM_000710, and NM 001386007, and the protein refseq at NP 000701.Methods of Use

[0110] In an embodiment methods are provided for treatment of conditions that benefit from activation of one or both of AGTR2 and BDKRB2, the method comprising administering to an individual in need thereof an effective dose of an agent of the disclosure, e.g. an active peptide or propeptide. Activation of AGTR2 and BDKRB2 have well-established roles in promoting vasodilation, anti-fibrosis effects, anti-inflammatory effects, tissue regeneration, and protective mechanisms against cardiovascular damage. AGTR2 activation is linked to vasodilation, anti-inflammatory effects, and reduced fibrosis. BDKRB2 activation promotes vasodilation via nitric oxide (NO) and prostacyclin. A dual BDKRB2 / AGTR2 agonist provides powerful antihypertensive and cardioprotective effects while avoiding AGTR1 -related side effects such as sodium retention and vasoconstriction.

[0111] Cardiovascular conditions that benefit from treatment with the agonist peptides of the disclosure include, for example, reducing hypertension, reducing risk of heart failure, stroke prevention, reducing risks associated with aneurysms, and the like.

[0112] The effectiveness of an antihypertensive agent may be assessed through a combination of immediate physiological changes and long-term risk reduction. Effective doses of the peptides of the disclosure may improve clinical indicia by at least about 10%, at least about 25%, at least about 50% or more. Parameters for efficacy of an anti-hypertensive include hemodynamic parameters (primary endpoints), such as reaching a target blood pressure, usually <130 / 80 mmHg, or a significant reduction from baseline bp, e.g., a drop of 10 mmHg systolic or 5 mmHg diastolic. Morning Surge is the ability of the agent to suppress the sharp rise in BP that occurs upon waking, which is a high-risk period for myocardial infarction and stroke. Cardiovascular outcomes(hard endpoints) include the ability to prevent "Major Adverse Cardiovascular Events" (MACE), reduction of stroke incidence; reduction of heart failure hospitalization, and reduction of all cause mortality. Organ protection (secondary / surrogate endpoints) is also of interest, e.g. for renal function a reduction in albuminuria (uACR) and stabilization of eGFR. For cardiac structure a reduction in Left Ventricular Mass Index (LVMI) (reversing hypertrophy). For vascular health a reduction in Pulse Wave Velocity (PWV), which measures arterial stiffness. For endothelial function, an improvement in Flow-Mediated Dilation (FMD) of the arteries.

[0113] The effectiveness of an agent for effectiveness in preventing or slowing the progression of aortic aneurysms primarily focus on reducing the rate of aneurysmal diameter expansion (growth rate), decreasing the incidence of rupture, and avoiding or delaying the need for surgical intervention. Effective doses of the peptides of the disclosure may improve clinical indicia by at least about 10%, at least about 25%, at least about 50% or more. The primary clinical outcome is Reduced Maximum Diameter Expansion Rate, i.e. a reduction in the growth rate of the aneurysm diameter, measured via imaging (CTA or ultrasound). Time to surgical threshold is a delay in the time it takes for an aneurysm to reach the surgical threshold. Lowered Rupture Rate is a significant reduction in the incidence of aortic rupture. Biomarkers include matrix metalloproteinase (MMP) inhibition, where decreased levels of MM P-9 and MMP-2, which are enzymes that degrade the structural matrix of the aortic wall, are indicators of efficacy. Decrease in C-reactive protein (CRP), interleukins (IL-1 p, IL-6), and other inflammatory markers is evidence of efficacy.

[0114] The effectiveness of an agent in treating heart failure may focus on reducing progression from Stage A / B to Stage C. Effective doses of the peptides of the disclosure may improve clinical indicia by at least about 10%, at least about 25%, at least about 50% or more. Indicia of interest may include structural and functional parameters (cardiac remodeling), where there is prevention or reversal of negative cardiac remodeling, typically measured via echocardiogram or cardiac MRI. Indicia include left ventricular ejection fraction (LVEF) to prevent a decline in LVEF or improves the percentage of blood pumped with each contraction. Left ventricular mass index (LVMI) to prevent the heart wall from thickening (hypertrophy). Left atrial volume index (LAVI) to maintain a normal LAVI. Diastolic function to prevent "stiffness" (diastolic dysfunction), which leads to heart failure with preserved ejection fraction (HFPEF). Biomarkers include NT-PROBNP or BNP, where an effective agent maintains NT- PROBNP levels <125 pg / ml. Stabilization of high-sensitivity troponin (HS-CTN), where persistent elevation indicates ongoing subclinical cardiomyocyte injury and effectiveness is measured by the stabilization or reduction of these levels. Effectivenessis also measured by how well the patient maintains their physical "reserve.", e.g. 6- minute walk test, or KCCQ score (Kansas City cardiomyopathy questionnaire).

[0115] Renal conditions are also of interest for treatment, e.g. in kidney pressure regulation.The agonist peptides of the disclosure find use in treating diabetic nephropathy by slowing progression to end-stage renal disease (ESRD) and reducing proteinuria.

[0116] The agonist peptides are useful in the treatment of fibrotic lung disease, including for example idiopathic pulmonary fibrosis (I PF), and can stabilize lung function in patients with I PF. The peptides may also be used in the treatment of individuals suffering from respiratory infections, e.g. severe COVID, etc. Effective doses may improve clinical indicia by at least about 10%, at least about 25%, at least about 50% or more. Measures of efficacy include, for example, stabilization of forced vital capacity (FVC); requirement for supplemental oxygen, requirement for mechanical ventilation; levels of C-reactive protein; and the like.

[0117] The effective dose of an agent of the disclosure may range up to about 30 mg / kg body weight, up to about 20 mg / kg, up to about 10 mg / kg, up to about 5 mg / kg; up to about 1 mg / kg, upto about 0.5 mg / kg; upto about 0.1 mg / kg; upto about 0.05 mg / kg; at least about 0.001 mg / kg, at least about 0.005 mg / kg, at least about 0.01 mg / kg, at least about 0.05 mg / kg, at least about 0.1 mg / kg, at least about 0.5 mg / kg, or more where the dose may vary with the specific agent and recipient.

[0118] The agents may be administered one or a plurality of days, and in some embodiments is administered daily, every two days, semi-weekly, weekly, etc. for a period of from about 1 , about 2, about 3, about 4, about 5, about 6, about 7 or more weeks, up to a chronic maintenance level of dosing. Therapeutic entities of the present invention are usually administered on multiple occasions. Intervals between single dosages can be weekly, monthly or yearly. Intervals can also be irregular as indicated by measuring blood levels of the therapeutic entity in the patient. Alternatively, therapeutic entities of the present invention can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the polypeptide in the patient.

[0119] In prophylactic applications, a relatively low dosage is administered at relatively infrequent intervals over a long period of time. Some patients continue to receive treatment for the rest of their lives. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, and preferably until the patient shows partial or completeamelioration of symptoms of disease. Thereafter, the patent can be administered a prophylactic regime.

[0120] In still yet some other embodiments, for prophylactic applications, pharmaceutical compositions or medicaments are administered to a patient susceptible to, or otherwise at risk of a disease or condition in an amount sufficient to eliminate or reduce the risk, lessen the severity, or delay the outset of the disease, including biochemical, histologic and / or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease.

[0121] In still yet some other embodiments, for therapeutic applications, therapeutic entities of the present invention are administered to a patient suspected of, or already suffering from such a disease in an amount sufficient to cure, or at least partially arrest, the symptoms of the disease (biochemical, histologic and / or behavioral), including its complications and intermediate pathological phenotypes in development of the disease. An amount adequate to accomplish therapeutic or prophylactic treatment is defined as a therapeutically- or prophylactically-effective dose. In both prophylactic and therapeutic regimes, agents are usually administered in several dosages until a sufficient response has been achieved.

[0122] According to the present invention, compositions can be administered by parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intracranial, intraperitoneal, intranasal, aerosol, or intramuscular means. The most typical route of administration is intravenous although other routes can be equally effective.

[0123] For parenteral administration, compositions of the invention can be administered as injectable dosages of a solution or suspension of the substance in a physiologically acceptable diluent with a pharmaceutical carrier that can be a sterile liquid such as water, oils, saline, glycerol, or ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, surfactants, pH buffering substances and the like can be present in compositions. Other components of pharmaceutical compositions are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, and mineral oil. In general, glycols such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions. Antibodies and / or polypeptides can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner as to permit a sustained release of the active ingredient. An exemplary composition comprises polypeptide at 1 mg / mL, formulated in aqueous buffer consisting of 10 mM T ris, 210 mM sucrose, 51 mM L-arginine, 0.01 % polysorbate 20, adjusted to pH 7.4 with HCI or NaOH.

[0124] Typically, compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles priorto injection can also be prepared. The preparation also can be emulsified or encapsulated in liposomes or micro particles such as polylactide, polyglycolide, or copolymer for enhanced adjuvant effect, as discussed above. Langer, Science 249: 1527, 1990 and Hanes, Advanced Drug Delivery Reviews 28: 97-119, 1997. The agents of this invention can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner as to permit a sustained or pulsatile release of the active ingredient.

[0125] Additional formulations suitable for other modes of administration include oral, intranasal, and pulmonary formulations, suppositories, and transdermal applications.

[0126] For suppositories, binders and carriers include, for example, polyalkylene glycols or triglycerides; such suppositories can be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1%-2%. Oral formulations include excipients, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, and magnesium carbonate. These compositionstake the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of active ingredient, preferably 25%-70%.

[0127] The pharmaceutical compositions are generally formulated as sterile, substantially isotonic and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration. Preferably, a therapeutically effective dose will provide therapeutic benefit without causing substantial toxicity.

[0128] Toxicity of the proteins described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LD50 (the dose lethal to 50% of the population) or the LD100 (the dose lethal to 100% of the population). The dose ratio between toxic and therapeutic effect is the therapeutic index. The data obtained from these cell culture assays and animal studies can be used in formulating a dosage range that is not toxic for use in human. The dosage of the proteins described herein lies preferably within a range of circulating concentrations that include the effective dose with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See, e.g., Fingl et al., 1975, In: The Pharmacological Basis of Therapeutics, Ch. 1).Formulations

[0129] As used herein, a "therapeutically effective amount" refers to that amount of the therapeutic agent sufficient to prevent, treat or manage a disease or disorder. Atherapeutically effective amount may refer to the amount of therapeutic agent sufficient to delay or minimize the onset of disease. A therapeutically effective amount may also refer to the amount of the therapeutic agent that provides a therapeutic benefit in the treatment or management of a disease. Further, a therapeutically effective amount with respect to a therapeutic agent of the invention means the amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment or management of a disease.

[0130] As used herein, the terms "prevent", "preventing" and "prevention" refer to the prevention of the recurrence or onset of one or more symptoms of a disorder in a subject as result of the administration of a prophylactic or therapeutic agent.

[0131] As used herein, the term "in combination" refers to the use of more than one prophylactic and / or therapeutic agents. The use of the term "in combination" does not restrict the order in which prophylactic and / or therapeutic agents are administered to a subject with a disorder. A first prophylactic or therapeutic agent can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second prophylactic or therapeutic agent to a subject with a disorder.

[0132] Determining a therapeutically or prophylactically effective amount of an agent, e.g. a peptide, can be done based on animal data using routine computational methods. In one embodiment, the therapeutically or prophylactically effective amount contains between about 0.01 mg and about 1 g of protein or peptide, etc., as applicable. In another embodiment, the effective amount contains between about 1 mg / kg and about 100 mg / kg of agent, as applicable. In a further embodiment, the effective amount contains between about 10 mg / kg and about 50 mg / kg of the agent, as applicable.

[0133] Administering the instant compositions can be effected or performed using any of the various methods and delivery systems known to those skilled in the art. The administering can be performed, for example, intravenously, orally, via implant, transmucosally, transdermally, intramuscularly, intrathecally, and subcutaneously. The following delivery systems, which employ a number of routinely used pharmaceutical carriers, are only representative of the many embodiments envisioned for administering the instant compositions.

[0134] Injectable drug delivery systems include solutions, suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-alteringagents (e.g., ethanol, propylene glycol and sucrose) and polymers (e.g., polycaprylactones and PLGA's). Implantable systems include rods and discs, and can contain excipients such as PLGA and polycaprylactone. Nucleic acids of the invention can also be administered attached to particles using a gene gun.

[0135] Oral delivery systems include tablets and capsules. These can contain excipients such as binders (e.g., hydroxypropylmethylcellulose, polyvinyl pyrilodone, other cellulosic materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulosic materials), disintegrating agents (e.g., starch polymers and cellulosic materials) and lubricating agents (e.g., stearates and talc).

[0136] Transmucosal delivery systems include patches, tablets, suppositories, pessaries, gels and creams, and can contain excipients such as solubilizers and enhancers (e.g., propylene glycol, bile salts and amino acids), and other vehicles (e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid).

[0137] Dermal delivery systems include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, liposomes, ointments, aqueous and nonaqueous solutions, lotions, aerosols, hydrocarbon bases and powders, and can contain excipients such as solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrolidone). In one embodiment, the pharmaceutically acceptable carrier is a liposome or a transdermal enhancer.

[0138] Solutions, suspensions and powders for reconstitutable delivery systems include vehicles such as suspending agents (e.g., gums, xanthans, cellulosics and sugars), humectants (e.g., sorbitol), solubilizers (e.g., ethanol, water, PEG and propylene glycol), surfactants (e.g., sodium lauryl sulfate, Spans, Tweens, and cetyl pyridine), preservatives and antioxidants (e.g., parabens, vitamins E and C, and ascorbic acid), anti-caking agents, coating agents, and chelating agents (e.g., EDTA).Antigen-Binding Proteins

[0139] Antigen binding region (ABR). As used herein, the term ABR refers to a combination of variable heavy (VH and variable light (VL) polypeptides to associate to form a variable region domain. An ABR of interest may be specific for CXCL14. Antibodies of interest may be agonist antibodies; antagonist antibodies; or antibodies that bind to CXCL14at a site that does not affect binding of the two proteins to each other, or their physiologic activity.

[0140] An ABR is the minimum antibody fragment that contains a complete antigenrecognition and binding site. This region consists of heavy- and one light-chain variabledomain in tight, non-covalent association, as a single polypeptide or as a dimer. It is in this configuration that the three CDRS of each variable domain interact to define an antigen-binding site on the surface of the domain. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

[0141] The term "variable" refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a p-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the p-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.

[0142] An antibody or ABR “which binds” an antigen of interest, is one that binds the antigen with sufficient affinity such that the antibody or binding molecule is useful as a diagnostic and / or therapeutic agent in targeting the antigen, and does not significantly cross-react with other proteins. In such embodiments, the extent of binding of the antibody or other binding molecule to a non-targeted antigen will usually be no more than 10% as determined by fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation (RIA).

[0143] An ABR may also be formulated as a single chain antibody. An ScFv is a polypeptide comprised of the variable regions of the immunoglobulin heavy and light chain of an antibody covalently connected by a peptide linker (Bird, etal. (1988) Science 242:423- 426; Huston, et a / . (1988) PNAS(USA) 85:5879-5883; S-z Hu, et al. (1996) Cancer Research, 56, 3055-3061. The generation of ScFvs based on monoclonal antibody sequences is well known in the art. See, e.g. The Protein Protocols Handbook, John M. Walker, Ed. (2002) Humana Press Section 150 “Bacterial Expression, Purification andCharacterization of Single-Chain Antibodies!’ Kipriyanov, S. Antibodies used in the preparation of scFvs may be optimized to select for those molecules which possess particular desirable characteristics (e.g. enhanced affinity) through techniques well known in the art such as phage display and directed evolution

[0144] In another embodiment, the ABR is a single domain antibody obtained through immunization of a camel or llama with a target cell derived antigen, in particular a tumor antigen. See, e.g. Muyldermans, S. (2001) Reviews in Molecular Biotechnology 74: 277-302. Alternatively, the ABD may be generated wholly synthetically through the generation of peptide libraries and isolating compounds having the desired target cell antigen binding properties in substantial accordance with the teachings or Wigler, et al. United States Patent No. 6303313 B1 issued November 12, 1999; Knappik, et al., United States Patent No 6,696,248 B1 issued February 24, 2004, Binz, et al. (2005) Nature Biotechnology 23:1257-1268, and Bradbury, etal. (2011) Nature Biotechnology 29:245-254.

[0145] The ABD may have affinity for more than one target antigen. For example, an ABD of the present invention may comprise chimeric bispecific binding members, i.e. have capable of providing for specific binding to a first target cell expressed antigen and a second target cell expressed antigen. Non-limiting examples of chimeric bispecific binding members include bispecific antibodies, bispecific conjugated monoclonal antibodies (mab)2, bispecific antibody fragments (e.g., F(ab)2, bispecific scFv, bispecific diabodies, single chain bispecific diabodies, etc.), bispecific T cell engagers (BiTE), bispecific conjugated single domain antibodies, micabodies and mutants thereof, and the like. Non-limiting examples of chimeric bispecific binding members also include those chimeric bispecific agents described in Kontermann (2012) MAbs. 4(2): 182-197; Stamova et al. (2012) Antibodies, 1 (2), 172-198; Farhadfar et al. (2016) Leak Res.49:13-21 ; Benjamin et al. Ther Adv Hematol. (2016) 7(3):142-56; Kiefer et al. Immunol Rev. (2016) 270(1):178-92; Fan et al. (2015) J Hematol Oncol. 8:130; May et al. (2016) Am J Health Syst Pharm. 73(1):e6-e13. In some embodiments, the chimeric bispecific binding member is a bivalent single chain polypeptides. See, e.g. Thirion, et al. (1996) European J. of Cancer Prevention 5(6):507-511 ; DeKruif and Logenberg (1996) J. Biol. Chem 271 (13)7630-7634; and Kay, et al. United States Patent Application Publication Number 2015 / 0315566 published November 5, 2015. In some instances, a chimeric bispecific binding member may be a bispecific T cell engager (BiTE).

[0146] A “functional” or “biologically active” antibody or antigen-binding molecule is one capable of exerting one or more of its natural activities in structural, regulatory, biochemical or biophysical events. For example, a functional antibody or other binding molecule may have the ability to specifically bind an antigen and the binding may in turnelicit or alter a cellular or molecular event such as signaling transduction or enzymatic activity. A functional antibody or other binding molecule may also block ligand activation of a receptor or act as an agonist or antagonist. The capability of an antibody or other binding molecule to exert one or more of its natural activities depends on several factors, including proper folding and assembly of the polypeptide chains.

[0147] The term “antibody” herein is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, monomers, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), heavy chain only antibodies, three chain antibodies, single chain Fv, nanobodies, etc., and also include antibody fragments, so long as they exhibit the desired biological activity (Miller et al (2003) Jour, of Immunology 170:4854-4861). Antibodies may be murine, human, humanized, chimeric, or derived from other species.

[0148] The term antibody may reference a full-length heavy chain, a full length light chain, an intact immunoglobulin molecule; or an immunologically active portion of any of these polypeptides, i.e., a polypeptide that comprises an antigen binding site that immunospecifically binds an antigen of a target of interest or part thereof, such targets including but not limited to, cancer cell or cells that produce autoimmune antibodies associated with an autoimmune disease. The immunoglobulin disclosed herein can be of any type (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g, lgG1 , lgG2, lgG3, lgG4, Ig A1 and lgA2) or subclass of immunoglobulin molecule, including engineered subclasses with altered Fc portions that provide for reduced or enhanced effector cell activity. The immunoglobulins can be derived from any species. In one aspect, the immunoglobulin is of largely human origin.

[0149] The term “variable” refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of variable domains are called the framework regions (FRs). The variable domains of native heavy and light chains each comprise four FRs, largely adopting a beta-sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the beta-sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al (1991) Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md.). The constant domains are notinvolved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC).

[0150] The term “hypervariable region” when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region may comprise amino acid residues from a “complementarity determining region” or “CDR”, and / or those residues from a “hypervariable loop”. “Framework Region” or “FR” residues are those variable domain residues other than the hypervariable region residues as herein defined.

[0151] Variable regions of interest include 3 CDR sequences, which may be obtained from available antibodies with the desired specificity, or may be obtained from antibodies developed for this purpose. One of skill in the art will understand that a number of definitions of the CDRs are commonly in use, including the Kabat definition (see “Zhao et al. A germline knowledge based computational approach for determining antibody complementarity determining regions.” Mol Immunol. 2010;47:694-700), which is based on sequence variability and is the most commonly used. The Chothia definition is based on the location of the structural loop regions (Chothia et al. “Conformations of immunoglobulin hypervariable regions.” Nature. 1989;342:877-883). Alternative CDR definitions of interest include, without limitation, those disclosed by Honegger, “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool.” J Mol Biol. 2001 ;309:657-670; Ofran et al. “Automated identification of complementarity determining regions (CDRs) reveals peculiar characteristics of CDRs and B cell epitopes.” J Immunol. 2008;181 :6230-6235; Almagro “Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires.” J Mol Recognit. 2004;17:132-143; and Padlanet al. “Identification of specificity-determining residues in antibodies.” Faseb J. 1995;9:133- 139., each of which is herein specifically incorporated by reference.

[0152] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations, which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier“monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.

[0153] The antibodies herein specifically include “chimeric” antibodies in which a portion of the heavy and / or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et al (1984) Proc. Natl. Acad. Sci. USA, 81 :6851-6855). Chimeric antibodies of interest herein include “primatized” antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g., Old World Monkey, Ape etc) and human constant region sequences.

[0154] An “intact antibody chain” as used herein is one comprising a full length variable region and a full length constant region. An intact “conventional” antibody comprises an intact light chain and an intact heavy chain, as well as a light chain constant domain (CL) and heavy chain constant domains, CH1 , hinge, CH2 and CH3 for secreted IgG. Other isotypes, such as IgM or IgA may have different CH domains. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof. The intact antibody may have one or more “effector functions” which refer to those biological activities attributable to the Fc constant region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include C1q binding; complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell- mediated cytotoxicity (ADCC); phagocytosis (ADCP); and down regulation of cell surface receptors. Constant region variants include those that alter the effector profile, binding to Fc receptors, and the like.

[0155] Depending on the amino acid sequence of the constant domain of their heavy chains, intact antibodies can be assigned to different “classes.” There are five major classes of intact immunoglobulin antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into “subclasses” (isotypes), e.g., lgG1 , lgG2, lgG3, lgG4, IgA, and lgA2. The heavy-chain constant domains that correspond to the different classes of antibodies are called a, 5, £, y, and p, respectively. The subunit structures and three- dimensional configurations of different classes of immunoglobulins are well known. Ig forms include hinge-modifications or hingeless forms (Roux et al (1998) J. Immunol.161 :4083-4090; Lund et al (2000) Eur. J. Biochem. 267:7246-7256; US 2005 / 0048572;US 2004 / 0229310). The light chains of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called K and A, based on the amino acid sequences of their constant domains.

[0156] Also within the scope of the invention are kits comprising the compositions of the invention and instructions for use. The kit can further contain a least one additional reagent. Kits typically include a label indicating the intended use of the contents of the kit. The term label includes any writing, or recorded material supplied on or with the kit, or which otherwise accompanies the kit.

[0157] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible. It is also understood that the terminology used herein is for the purposes of describing particular embodiments.

[0158] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or only and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

[0159] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the appended claims.EXPERIMENTAL

[0160] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

[0161] GPCR-CXCL14 variant interaction modeling using AlphaFold-Multimer v2. All class A and class B G protein-coupled receptors (GPCRs) were curated from GPCRdb or UniProt. Receptor sequences were filtered to include full-length sequences (containing all annotated transmembrane domains were included). For proteins with multiple isoforms, the UniProt-designated canonical isoform was selected. Fourteen CXCL14 C-terminal truncation variants were generated by sequential truncation of the native sequence beginning at residue 59K and terminating at residue 73R. Protein-peptide complexes were modeled using AlphaFold-Multimer (version 2) with default multimer settings unless otherwise specified. For each receptor-ligand pairing, five independent models were generated using distinct random seeds , yielding approximately 5 models per receptor-ligand pairing (approximately 25,000 models total). Multiple sequence alignments (MSAs) were generated using MMseqs2 and HHsearch. Template usage was disabled; when enabled, templates were drawn from the PDB. Positive control complexes consisted of experimentally validated receptor-chemokine pairs for class A and class B receptors. Negative controls were constructed by pairing CXCL14 variants with chemokine receptors, selected to represent phylogenetically related but functionally distinct receptors. Predicted complexes were evaluated using standard AlphaFold confidence metrics, including predicted aligned error (PAE) and per-residue confidence scores (pLDDT).

[0162] AlphaFold v3 peptide docking of short CXCL14 truncations. Short CXCL14-derived peptides (8 amino acids in length), corresponding to C-terminal truncations terminating in residues 60R through 73R were modeled with B1R, B2R, AT1 R and AT2R using AlphaFold v3. For each peptide-receptor pair, independent predictions were generated using multiple seeds. MSAs and structural templates were not used. Ligand representation was specified as peptide chain on AF3 setup. Predicted complexes were evaluated using AlphaFold-derived confidence metrics, including pLDDT and PAE. Binding affinity and interaction likelihood were further assessed using a Radial Topological Convolutional Neural Network (RTCNN), a novel physics-aware Al scoring function trained to predict binding affinity and well-suited for assessing physical validity and favorability of molecular interactions. Peptide-receptor interactions were considered high-confidence if they met the established thresholds for pLDDT, PAE and RTCNN. Representative structures were selected based on ranking and structural visualizations were generated using ChimeraX (version 1.8). All modeling was performed on the Sherlock high-performance computing cluster (Stanford Research Computing Center) using NVIDIA V100 / A100 class GPU-enabled nodes.Reproducibility was ensured by providing all input sequences, random seeds, and model outputs via a secure repository.

[0163] Cell lines and constructs. Chinese hamster ovary (CHO) cells expressing receptors N- terminally tagged with an HA epitope were used together with an NFAT-driven luciferase reporter (pGL4.30 [luc2P / NFAT-RE / Hygro], Promega, Cat. # E8481) for calcium mobilization assays. Cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 1x non-essential amino acids (NEAA), and 1 x penicillin-streptomycin (100 U / mL penicillin and 100 pg / mL streptomycin), at 37 °C in a humidified atmosphere containing 5% CO2.

[0164] PRESTO-Tango HTLA cells (modified HEK293T cells stably expressing a tTA- dependent luciferase reporter and p-arrestin2-TEV fusion protein) were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 pg / mL puromycin, and 100 pg / mL hygromycin B, in a humidified atmosphere at 37 °C with 5% CO2. For transient transfection, cells were seeded at a density of 2-4 x 10scells per 100-mm culture dish and allowed to adhere for -16-24 h to reach -70-80% confluency. Cells were transfected using Lipofectamine 3000 (Thermo Fisher Scientific, Cat. # L3000001) following the manufacturer’s protocol. PRESTO-Tango receptor constructs encoding human B2R (BDKRB2). B1 R (BDKRB1), AT1 R (AGTRT), AT2R (AGTR2), RXFP3 (RXFP3), GPR15 (GPR75)and MRGPRX2 (MRGPRX2) were obtained from Addgene.

[0165] CXCL14 quantification by ELISA. CXCL14 concentrations were measured using a DuoSet ELISA kit (R&D Systems, cat# DY866) according to the manufacturer’s instructions. Briefly, cell culture supernatants were collected and applied to plates precoated with capture antibody. Following incubation and washing, a detection antibody was added, followed by substrate development. Absorbance was measured at 450 nm with wavelength correction at 540 nm using a SpectraMax M5e plate reader (Molecular Devices). CXCL14 concentrations were calculated by interpolation from a standard curve generated with recombinant CXCL14.

[0166] PRESTO-Tango [3-arrestin assays. PRESTO-Tango [3-arrestin recruitment assays were performed in HTLA cells (modified HEK293T) maintained as described above. For peptide stimulation experiments, receptor transfected cells were treated with synthetic peptides (3 pM unless otherwise noted) and incubated for 16 h at 37 °C prior to measurement. For co-expression experiments, cells were co-transfected with Tango receptor constructs and CXCL14 expression constructs encoding full-length or C- terminally truncated variants. Luciferase activity was measured 48 h post-transfection. Luciferase activity was quantified using the Bright-Glo luciferase assay system (Promega cat #E2610) according to the manufacturer’s instructions and recorded asrelative luminescence units (RLU). For dose-response experiments, peptides were applied in 10-fold serial dilutions. Data were normalized to the maximal response elicited by cognate agonists (bradykinin for B2R, des-Arg9-bradykinin for B1 R, and angiotensin II for AT1 R and AT2R), defined as 100%. Data are mean ± s.e.m. of n = 5- 17 biological replicates from 3-7 independent experiments, each performed in 2-3 technical replicates. Statistical analyses were performed using Graph Pad Prism. Data are presented as mean ± s.e.m.. One-way ANOVA with Tukey’s post hoc test was used for multiple comparisons. For combined analyses across independent experiments, mixed-effects models were applied with experimental date as a random effect. P < 0.05 was considered statistically significant.

[0167] B1R inhibition assays. B1 R inhibition was assessed using PRESTO-Tango p-arrestin recruitment assays in HTLA cells (modified HEK293T) maintained as described above. Cells were transiently transfected with B1 R Tango constructs and seeded in 96-well plates at a density of 2-3 x 104cells per well. For inhibition assays, cells were preincubated with test peptides (68W, 61 F, and indicated controls) at 3 pM for 15 min at 37 °C, followed by stimulation with equimolar agonist (des-Arg9-bradykinin or bradykinin, 3 pM). Cells were then incubated for 16 h at 37 °C prior to measurement. Agonists were applied in increasing concentrations (10-fold serial dilutions) to define conditions under which maximal inhibition by test peptides could be observed. Luciferase activity was quantified using Bright-Glo luciferase assay system (Promega cat #E2610)and recorded as relative luminescence units (RLU). Data were normalized to agonist-only control responses, defined as 100%. Data are presented as mean ± s.e.m. from three independent experiments, each performed with two technical replicates per condition. Statistical significance was assessed using one-way ANOVA followed by Tukey’s multiple comparisons post hoc test.

[0168] Calcium mobilization assay. CHO cells stably expressing human B2R (HA-tagged) were seeded in 96-well black-walled plates (Greiner Bio-One, cat# 07-000-166) at a density of 2-3 x 104cells per well and incubated for 16-24 h prior to assay. Cells were loaded with a calcium-sensitive fluorescent dye (BD Biosciences PBX calcium assay kit, cat# 640175) for 30 min at 37 °C according to the manufacturer’s instructions. Cells were stimulated with 1 pM peptide 68W or 1 pM bradykinin (positive control), with vehicle as negative control and fluorescence was recorded in kinetic mode using a Molecular Devices SpectraMax M5e multimode plate reader at excitation / emission wavelengths of 485 / 525 nm with an emission cutoff filter set at 515 nm. Measurements were acquired at a 30 seconds interval for 1 hour at 37 °C. Data were normalized to baseline fluorescence (AF / F0), where Forepresents the mean fluorescence prior to stimulation for each well. Data are presented as mean ± s.e.m., with each conditiontested in 3 technical replicates per experiment and experiments repeated 3 times. Statistical significance was assessed using one-way ANOVA with Tukey’s multiple comparison post hoc test.

[0169] Cold competitive binding assay of CXCL14 68W binding to B2R. OHO cells stably expressing human B2R were incubated in binding buffer (HBSS supplemented with Ca2+ / Mg2+and 2% (v / v) fetal bovine serum) for 30 min at 4°C with 300 nM FAM-labeled CXCL14 68W (“tracer”). For cold competition binding assays, B2R-expressing CHO cells were pre-incubated for 10 min with increasing concentrations (0.3nM-1 LIM) of IgG Fc-CXCL14_68W competitor in binding buffer at 4°C. The tracer was then added at a final concentration of 300 nM and incubated for 30 min on ice. Following incubation, cells were washed with PBS supplemented with 0.5% (w / v) BSA and analyzed by flow cytometry using a Cytek Aurora. Data were acquired and analyzed as mean fluorescence intensity (MFI). Competition binding curves were fitted using nonlinear regression (four-parameter logistic model) in GraphPad Prism to determine IC50values. Data are presented as mean ± s.e.m. of three technical replicates and are representative of two independent experiments.

[0170] Single-cell RNA-seq and spatial transcriptomics. Publicly available scRNA-seq datasets were analyzed for co-expression of CXCL14 and BDKRB2. mouse aortic root atherosclerotic plaques (Cheng / Quertermous labs), human coronary artery, human skin (normal and wound healing time course, and mouse dermal paw tissue. Xenium spatial transcriptomic analysis of mouse atherosclerotic aortic root was performed in the Cheng / Quertermous labs. RNAscope for CXCL14 was performed on human tongue sections. Data were processed using standard Seurat / Scanpy pipelines with quality control, normalization, dimensionality reduction and clustering.

[0171] Animals. Animal procedures were approved by the Stanford University Institutional Animal Care and Use Committee (IACUC) and the VA Palo Alto IACUC and were conducted in accordance with institutional guidelines. BALB / c wild-type, C57BL / 6 wildtype, Cxcl14 / (B6;129P2-Cxcl14 tm1 Litt / J, JAX labs), and Kng1 / Kng2 double knockout (bradykinin-deficient) mice (M Takano) were used in this study. Mice were housed under specific pathogen-free conditions on a 12-h light / dark cycle with ad libitum access to food and water.

[0172] Synthetic peptides and palmitoylated conjugates. Peptides were synthesized by solidphase synthesis and purified to >95% by HPLC. Sequences: 68W, SEQ ID NO:8 KLQSTKRFIKWYNAW; 77E SEQ ID NO:11 KLQSTKRFIKWYNAWNEKRRVYEE; 61 F SEQ ID NO:12, KLQSTKRF; and additional truncation variants as described in Table 1. Palmitoylated peptides were dissolved in 10% Captisol (CyDex Pharmaceuticals).Vehicle controls corresponding to each formulation were included. Palmitoyl-68W and palmitoyl-77E were generated by N-terminal conjugation of palmitic acid (SEQ ID NO:8 palm-KLQSTKRFlKWYNAW and SEQ ID NO:11 palm- KLQSTKRFIKWYNAWNEKRRVYEE, respectively and dissolved in 10% captisol). Peptide vehicle served as negative control. FAM-68W was labeled at the N-terminus. IgG Fc-CXCLI 4 68W was produced by mammalian expression. Throughout this work, the CXCL14 68W truncate (SEQ ID NO:33) refers to the synthetic, FAM-labeled, refolded preparation obtained from Phoenix Peptide; the FAM label is called out explicitly only when fluorescence is the readout. A CXCL14_68W-encoding expression vector was used separately in PRESTO-Tango co-transfection experiments (see Cell lines and constructs).

[0173] Evans blue (Miles) assay for vascular leakage. Vascular permeability was assessed using the Evans blue Miles assay. Mice were anesthetized with 2% isoflurane and injected intravenously via retro-orbital injection with 100 pL of 1 % (w / v) Evans blue dye (Sigma-Aldrich) in sterile saline, with or without the selective bradykinin B2 receptor antagonist Icatibant (Tocris; HOE 140, cat# 3014; 2.5 pg per mouse, -0.1-0.125 mg / kg). After 20 min, 50 pL of peptide (100 pM) or saline control was administered by intradermal injection into the dorsal skin. Injection sites were spatially separated to avoid overlap. Mice were euthanized 10 min following intradermal injection, and skin at injection sites was excised. Evans blue extravasation was quantified by image-based morphometric analysis using Imaged. Images of excised skin were acquired under standardized illumination and exposure settings, and the area and mean intensity of dye extravasation were measured and normalized to background signal. Data are presented as mean ± s.e.m. from three independent experiments. Statistical significance was assessed using one-way ANOVA with Tukey’s multiple comparisons test.

[0174] Blood pressure measurements. Blood pressure and heart rate were measured in conscious mice using a non-invasive tail-cuff system (CODA, Kent Scientific). Mice were acclimatized to the restraint chamber and tail-cuff apparatus for 3-5 consecutive days prior to data collection, and baseline measurements were obtained before experimental interventions. All experiments were performed in male mice (age 12-15 weeks). For acute studies, mice were administered peptides or vehicle by subcutaneous injection, and systolic blood pressure and heart rate were recorded at 5- min intervals starting 15 min post-injection for 30 minutes. For chronic studies, hypertension was induced by continuous subcutaneous infusion of angiotensin II (1.5 mg / kg / day) using osmotic minipumps (Alzet model 2004; DURECT Corporation). Mice received daily subcutaneous injections of palm-68W (300 pg / day), equimolar doses ofpalm-77E or mutant 77E (W68A), or vehicle (10% captisol, 100 microliters). Data are presented as mean ± s.e.m. Statistical significance was assessed using two-way repeated- measures ANOVA with Sidak’s multiple comparisons post hoc test. For each time point, 15-20 measurement cycles were recorded and averaged. Measurements were performed at the same time of day to minimize circadian variation.

[0175] Echocardiography. Cardiac function was assessed by transthoracic echocardiography in 15-week-old male C57BL / 6 mice following 4 weeks of angiotensin II infusion (1.5 mg / kg / day, subcutaneous osmotic minipump) with or without daily subcutaneous administration of palm-68W or palm-77E (300 pg / day; n = 5 per group) or vehicle (n = 4), compared to no-angiotensin II controls (n = 5). Echocardiographic measurements were performed under light anesthesia with [1-2% isoflurane], and body temperature was maintained at 37 °C throughout imaging. Two-dimensional and M-mode images were acquired in the parasternal short-axis view using a high-resolution ultrasound system (Vevo 2100) using 40Mhz transducer. Left ventricular ejection fraction (EF) and fractional shortening (FS) were calculated from M-mode measurements using standard formulas and averaged over 3-5 cardiac cycles. Data are presented as mean ± s.e.m. Statistical significance was assessed using two-tailed Student’s t-test.

[0176] Local irritation (itch) scoring. Local irritation was assessed by quantifying scratching behavior following intradermal peptide administration. Adult male C57BL / 6 mice (12 weeks old) were injected intradermally in the dorsal skin with 68W or 77E (100 pM in 50 pL saline), with saline injected at a contralateral site as an internal control. Following injection, mice were individually placed in observation chambers and video-recorded for 20 min. Scratch bouts, defined as a continuous series of hindlimb scratching movements directed toward the injection site, were manually quantified from recordings by an observer blinded to treatment conditions. Data are presented as mean ± s.e.m. The experiment was performed twice with n = 2 mice per condition per experiment. Statistical significance was assessed using an unpaired two-tailed t-test.

[0177] Bulk RNA-seq and gene set enrichment analysis. RNA was extracted from heart and suprarenal aorta from 1-week Angll-infused mice (n=4-5 / group). Libraries were prepared using standard protocols and sequenced on Illumina platforms. Differential gene expression was analyzed using DESeq2. Gene set enrichment analysis was performed using clusterProfiler with Hallmark, Reactome and Human Phenotype Ontology gene sets. Results were filtered at FDR <= 0.05 and visualized as bubble plots showing normalized enrichment scores (NES, color) and -log10(FDR) (size).

[0178] Protease co-transfection and B2R reporter assays. CHO cells were co-transfected with full-length CXCL14 and expression constructs encoding active proteases, including kallikrein-related peptidase 7 (KLK7), chymase (CMA1), and endothelin-convertingenzyme 1 (ECE1), or a catalytically inactive KLK7 mutant (H57A / D102N / S195A). Conditioned media were collected 24h, 48 h and 72h post-transfection, clarified by centrifugation, and used for downstream assays. CXCL14 expression was assessed by SDS-PAGE followed by immunoblotting using anti-his antibody (R&D Systems cat# MAB050H-SP). CXCL14 concentrations in conditioned media were quantified by ELISA (R&D Systems; DuoSet, cat# DY866) and normalized across samples prior to functional assays. Conditioned media containing 300 nM CXCL14 were applied to CHO NFAT luciferase reporter cells stably expressing human B2R for 6 h at 37 °C. Luciferase activity was then measured as relative luminescence units (RLU) using Bright-Glo luciferase assay system (Promega cat #E2610). Data are presented as mean ± s.e.m. from three independent experiments. Statistical significance was assessed using two- way ANOVA followed by Sidak’s multiple comparisons post hoc test.

[0179] Mass spectrometry of protease cleavage products. Full-length CXCL14 or synthetic C- terminal peptide substrates (short 70E SEQ ID NO:22, FIKWYNAWNE) were incubated with candidate proteases at a 1000:1 substrate-to-enzyme molar ratio for 6 h at 37 °C in 1x PBS (pH 7.4). Recombinant KLK7 was activated by thermolysin treatment in activation buffer (50 mM Tris, 10 mM CaCI2, 150 mM NaCI, 0.05% Brij-35, pH 7.5) at 37 °C for 2 h, followed by quenching with EDTA (final concentration 50 mM). Recombinant chymase was matured by incubation with cathepsin C in maturation buffer (50 mM MES, pH 5.5) in the presence of heparin at room temperature for 1 h. Maturation was terminated by addition of N-ethylmaleimide (NEM; Sigma-Aldrich, cat# E1271) to a final concentration of 3 mM. Cleavage products were analyzed by liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS / MS) using a Thermo Fisher Orbitrap mass spectrometer coupled to a nanoLC system equipped with a uPAC C18 column. Data were acquired in positive ion mode using data-dependent acquisition, and MS / MS spectra were generated by collision-induced dissociation. Peptide identities were assigned based on measured m / z values and fragmentation spectra matched to predicted CXCL14-derived peptides. For KLK7, CID- based microsequencing confirmed the identity of the released blocking peptide NEKRRVYEE. Chymase and ECE1 cleavage products were mapped based on m / z values and retention time analysis.

[0180] Abdominal aortic aneurysm model. Experimental AAAs were induced in 10-weeks-old male C57BL / 6J mice via topical application of porcine pancreatic elastase to exposed intrarenal aorta under anesthetic and sterile conditions (PMID: 34320253). Animals were treated daily by subcutaneous injection of peptide palm-77E (300 pg / mouse / day) or an equal volume of vehicle beginning one day prior to AAA induction for 14 days. AAAs were imaged via the serial measurements of transverse luminal intrarenal aorticdiameters using transabdominal ultrasonography. At sacrifice (14 days after AAA creation), aortas were harvested, and acetone-fixed frozen sections were prepared for the assessments of aneurysmal pathologies (PMID: 37168662, 37158066).

[0181] Statistical analysis. Data are presented as mean ± s.e.m or S.D., unless otherwise indicated. Statistical analyses were performed as described in the corresponding figure legends and included unpaired two-tailed Student’s t-tests, one-way ANOVA with Tukey’s or Dunnett’s multiple comparisons tests, two-way repeated-measures ANOVA with Sidak’s multiple comparisons test, and mixed-effects models for multi-experiment Tango datasets. All tests were two-sided unless otherwise specified. A Rvalue < 0.05 was considered statistically significant. Statistical analyses were performed using GraphPad Prism (v10) and R (v4.3). n refers to independent biological replicates unless otherwise indicated. Technical replicates were averaged prior to analysis. Investigators were blinded to treatment groups where applicable, and animals were randomly assigned to experimental groups.Example 1

[0182] Dysregulation of vascular tone, endothelial integrity, and inflammatory signaling underly a broad spectrum of cardiovascular and related diseases. While bradykinin (BK) and angiotensin II (Angll) signaling via GPCRs is central to vascular control, our understanding of how vascular tone and inflammatory responses are regulated through these vasoactive receptors remains incomplete. Here we identify CXCL14, a widely expressed orphan chemokine with protective roles in stroke and sepsis, as a novel proteolytically activated modulator of vascular GPCR signaling.

[0183] Vascular dysfunction contributes to hypertension, stroke, heart attack, kidney disease, diabetes, and neurodegeneration and other chronic diseases. Our research has uncovered a novel mechanism that regulates the vasculature by activating specific "vaso-protective" receptors to support vascular health. By defining how this pathway operates and its effects on vascular tone and inflammation, our studies provide therapeutic approaches to prevent or mitigate vascular damage across a wide spectrum of diseases. The amino acid sequence of the human CXCL14 propeptide is as shown in SEQ ID NO:1.

[0184] Our analyses demonstrate that CXCL14 (SEQ ID NO: 1 , also referred to as “X14”) is activated by chymotryptic protease(s). We identify CXCL14 peptides that selectively activate the vasoprotective receptors B2R and AT2R, but are either inactive or inhibitory towards their more classically pathogenic counterparts B1 R and AT1 R. These results thus identify a novel mechanism for vascular homeostasis and response through differential vasoactive GPCR control. We hypothesize that CXCL14 is vasoprotectiveand regulates vascular tone, inflammatory responses, and endothelial barrier functions. These findings are transformative for understanding of vascular control mechanisms and new therapies for cardiovascular diseases including hypertension and stroke.

[0185] CXCL14 (CXCL14) is an orphan chemokine with roles in development and disease.CXCL14 is conserved in evolution from coelacanths. Its deletion in mice results in partial perinatal lethality, suggesting a fundamental role in physiology. CXCL14- transgenic mice show attenuated sepsis-induced acute kidney injury, reduced bacterial load, and improved short-term survival rates. Similarly, CXCL14 overexpression alleviates ventilator-induced lung injury by downregulating pro-inflammatory cytokine production. Therapeutic systemic administration of CXCL14 protein is also protective in disease models associated with vascular dysfunction: it enhances survival and bacterial clearance in sepsis and reduces infarct size in models of stroke. Conversely, CXCL14 transgenic mice exhibit exacerbated collagen-induced arthritis. These animal studies highlight pleiotropic functions of CXCL14, which appears to function most often as a homeostatic protective factor but can also have pro-inflammatory roles depending on context. In humans, CXCL14 expression correlates with better outcomes in coronary artery disease, consistent with a proposed protective role, and its expression correlates with clinical prognosis in several cancers. CXCL14 is scavenged by ACKR2, antagonizes CXCL12-CXCR4 signaling, and like many small peptides triggers the promiscuous mast cell peptide receptor MRGPRX2, but physiological receptors that could explain its biology and strict evolutionary conservation have remained elusive.

[0186] We identify a C terminally truncated CXCL14, hereafter "CXCL14 68W" or equivalently “X14 68W” (SEQ ID NO:33) that activates the vasoactive peptide receptors B2R and AT2R. A 15 amino acid (AA) alpha helical peptide ending in 68W (referred to here as "68W", SEQ ID NO:8) from the CXCL14 C terminus is sufficient for receptor activation. Our data show that the active chemokine "CXCL14 68W" and peptide "68W" signal via B2R and AT2R, but not by other receptors tested including AT1 R, B1R and the paralogous relaxin receptors RXFP3 and 4. We show that 68W does not activate hypertension-associated AT1 R or the pro-inflammatory B1 R, but instead that 68W inhibits B1 R.

[0187] Our studies reveal that the active CXCL14 peptide 68W exerts robust B2R-dependent effects, including transient acute vascular leakage and reduced blood pressure. The vaso-protective role of CXCL14 was assessed in models of cardiovascular injury, and evaluating the therapeutic effects of CXCL14 peptide administration. CXCL14 is activated by chymotryptic proteases that cleave the chemokine at 68W to regulate vascular homeostasis and responses in inflammation. Mass spectrometry was used to define cleavage sites for candidate proteases, and functional assays to confirm theirability to generate the active chemokine. In vivo activation of B2R responses by CXCL14-activating proteases was assessed in the vascular leakage assay, comparing protease-induced leakage with or without inhibition of B2R by icatibant.

[0188] This work identifies a previously unrecognized endogenous mechanism for vasoregulation — protease-driven generation of peptides that selectively activate B2R and AT2R while bypassing (or inhibiting) B1 R and AT1 R. By revealing a novel, proteolytically regulated peptide axis with dual vasoprotective GPCR selectivity, our findings redefine the paradigm of GPCR signaling in vascular biology and inflammation. Our data shows that the unique polypharmacologic profile of CXCL14 peptides is governed not only by receptor specificity but also by upstream enzymatic cascades that generate active and inhibitory CXCL14 fragments.

[0189] Bioinformatic analyses of CXCL14. CXCL14 is a classical chemokine. It is broadly and constitutively expressed by multiple cell types including fibroblasts and pericytes, a feature that is often associated with pro- molecules that require proteolytic activation for receptor binding and function. Structurally this hypothesis is supported by a unique feature of CXCL14: a conserved C-terminal alpha helical peptide extension from the chemokine domain that comprises evolutionarily conserved potential protease cleavage sites, including a conserved canonical chymotryptic site at tryptophan 68W, see FIG. 1. Co-evolution analysis implicates CXCL14 in cell-cell contacts and barrier functions: the top 200 genes whose evolutionary changes most correlate with those of CXCL14 include multiple connexins, cadherins and tight junction proteins (see FIG. 2 GO term analysis).

[0190] Identification of B2R as a functional receptor for CXCL14 peptides terminating in 68W.To identify candidate receptors for C-term-CXCL14 variants, we modeled interactions of all class A and B GPCRs with fourteen CXCL14 C-terminal truncation variants using Alphafold2 in silico screening (5 models / pairing; -25000 models in total). Controls included 1) confirmation that modeling identified extracellular interaction and insertion of activating peptides in known receptor-ligand pairs; and 2) failure of CXCL14 variants to occupy the binding pockets of known chemokine receptors.

[0191] The results identified the bradykinin and angiotensin receptors as candidate receptors for proteolytically processed CXCL14. These receptors, particularly B2R, represented attractive candidates for several reasons: The BK and Angll receptors are closely related to each other and to known receptors for chemokines and chemokine-like ligands such as GPR15 and GPR25 (FIG. 3). The BK receptors have negatively charged N termini (pl 4.3 or 4.7), a characteristic of receptors that bind positively charged chemokines like CXCL14. Although the AT1 and AT2 receptor N termini aremore neutral, they share with the BK receptors ST rich sequences - potential O-linked glycosylation sites - which when glycosylated would serve to bind the positively charged chemokine. B2R was especially interesting as a candidate receptor because it is critically involved in regulation of cell-cell junctions and vascular permeability, correlating with the roles of CXCL14 suggested by coevolution analysis. B2R and CXCL14 also share known biology including parallel roles in browning of white fat and favorable regulation of thermogenesis and insulin sensitivity.Example 2CXCL14 68W and C terminal peptide 68 W activate B2R and AT2R in cell-based reporter assays.

[0192] Based on these in silico results and our hypothesis that the CXCL14 C terminus is proteolytically processed to reveal a C-term activation peptide, we set out to assay CXCL14 and candidate CXCL14 C-terminal truncation mutants (Table 1) for binding and signaling through candidate receptors. We used the PRESTO-Tango reporter system. In the Tango system, HEK293T cells stably expressing a luciferase reporter construct are transfected with receptors of interest and either treated with synthetic peptides or co-transfected with expression constructs encoding candidate ligands. Following 16-hour incubation, luciferase expression is quantified. The results revealed that CXCL14 truncated at 68W is a selective agonist of B2R and AT2R:

[0193] Co-transfection of receptors with CXCL14-truncation mutant CXCL14 68W (the chemokine with truncated C-term ending at 68W), or incubation of transfected receptors with synthetic peptide "68W" (comprising the C-terminal alpha helix truncated at 68W: SEQ ID NO:8 KLQSTKRFIKWYNAW) activated signaling through B2R and AT2R (FIG.4, FIG. 5). CXCL14 68W and 68Walso activated AT2R but did not activate B1 R, AT1 R, or other related receptors including RXFP3, GPR15 and MRGPRX2. Full-length CXCL14 and the shorter truncation variant CXCL14 63K failed to activate any receptor tested, indicating that the C-terminal residues beyond W68, the C terminal AA of peptide 68W and CXCL14 68W, act as an autoinhibitory domain. Co-transfection with CXCL14 63K, or with full length CXCL14, failed to activate the receptors. Titrations revealed that in this assay 68W showed similar EC50 to bradykinin on B2R and to Angll on AT2R (FIG. 5). CXCL14 68W and 68W only activated B2R and AT2R, and not B1 R or AT1 R or other receptors tested.

[0194] Assay results for receptor activation by CXCL14 constructs and peptides using the PRESTO-Tango system are summarized in Table 1 , which lists the peptides that were tested. Data for truncated chemokine variants CXCL14 68W and CXCL14 63K are replicated from FIG. 4. Data for peptide 68W are also shown with titration in FIG. 5. Thedata support uniquely strong receptor activation by 68W compared to other peptides tested. No CXCL14 peptides tested to date robustly activated B1 R or AT1 R.

[0195] While our Alphafold2 screens showed in silica interactions of CXCL14 68W with B1 R as well as B2R, the ligand failed to activate B1 R in reporter assays (FIG. 4, FIG. 6). We therefore assayed whether the 68W or other CXCL14 peptides inhibit B1 R. Candidate inhibitory peptides were pre-incubated with receptor transfectants for 15 min. prior to agonist stimulation. Peptides 68W and 61 F inhibited B1 R signaling in response to BK or des-Arg-BK (FIG. 6). Tested peptides did not activate B1 R (p > 0.4 vs. receptor alone), confirming results in TABLE 1 .

[0196] These results define a dual-function model in which CXCL14 peptides selectively activate B2R and AT2R while suppressing inflammatory B1 R signaling.Example 3CXCL14 peptide calcium mobilization, NFAT signaling and binding to human B2R

[0197] The Tango assay employs an engineered C-terminal signaling domain for p-arrestin readout. To confirm activation of human receptor with the native intracellular signaling sequence, we assessed calcium mobilization in CHO cells stably expressing human B2R. In an initial peptide screen, multiple CXCL14-derived peptides were evaluated; as for the Tango reporter, 68W was the most potent peptide in the Ca2+-dependent signaling assay (FIG. 7A).

[0198] In optimized kinetic assays, stimulation with 1 uM 68W produced a rapid, timedependent increase in intracellular calcium (measured as AF / F0), with magnitude and kinetics comparable to those observed with bradykinin. Vehicle-treated cells remained at baseline throughout the recording period (FIG. 7B). These results show that 68W activates calcium signaling through human B2R, independent of engineered reporter systems.

[0199] 68W and CXCL14_68W also activated the NFAT / Ca2+pathway through B2R as assessed using Promega's transcriptional NFAT reporter vector for Gq / Ca2+signaling in CHO cells stably expressing human B2R (FIG. 70). Synthetic CXCL14 68W truncate (Phoenix Peptide, Inc.) activated the pathway with potency similar to that of synthetic peptide 68W.

[0200] A mammalian-expressed IgG Fc-CXCL14 68W construct activated NFAT reporter signaling in B2R-expressing CHO cells at nanomolar concentrations (FIG. 7C), displaying greater potency than synthetic 68W peptide or synthetic CXCL14_68W which activated calcium mobilization at low micromolar concentrations.

[0201] Receptor binding: To complement functional assays, we directly evaluated ligandreceptor binding. Direct binding of CXCL14_68W to B2R was confirmed usingfluorescently labeled FAM-CXCL14 68W, which bound B2R-expressing CHO cells and was competed by unlabeled Fc-CXCL14_68W with an IC50 of ~20 nM (FIG. 7D). This IC50 is higher than the functional EC50 of Fc-CXCL14_68W estimated from the NFAT / Ca2+reporter (sub-nanomolar; FIG. 70), consistent with substantial receptor reserve in the Gq-Ca2+-calcineurin-NFAT signaling cascade in which functional EC50 reflects the fractional receptor occupancy needed to saturate downstream signal amplification rather than the absolute affinity of the ligand-receptor interaction.

[0202] The enhanced potency of the bivalent Fc fusion over monomeric forms (synthetic 68W peptide and synthetic CXCL14 68W truncate, both with functional EC50 in the low micromolar range; FIG. 7C) is consistent with avidity-driven engagement of B2R by the bivalent ligand. More generally, multivalent presentations of the disclosed C-terminal CXCL14 peptides — including without limitation dimers and higher-order oligomers, fusions to dimerizing scaffolds (e.g., IgG Fc, leucine zippers, coiled coils), conjugates to multivalent carriers, and peptides displayed on or tethered to glycosaminoglycan- presenting matrices — are expected to provide enhanced functional potency relative to monomeric peptides. This finding parallels the multivalent presentation expected for endogenous CXCL14 displayed on cell-surface and extracellular-matrix glycosaminoglycans.

[0203] Results are summarized in FIG. 8, which relates the unique polypharmacology of CXCL14 to the known biology of its target receptors, showing a fundamental role for the chemokine in vascular homeostasis and pathogenesis.Example 4Alphafold in silico modeling

[0204] To explore potential modes and poses for CXCL14-derived peptide interactions with GPCRs, we performed Alphafold3 modeling of CXCL14 68W, and of CXCL14 C terminal peptides with the BK and Angiotensin receptors. In high scoring Alphafold models, CXCL14 68W displays coordinated charge-based chemokine domain interactions with B2R extracellular loops and extensive interactions of the C terminal peptide with key binding pocket amino acids. Modeling of additional peptides form the CXCL14 C terminal helical domain reveal additional peptide interactions that correlate with or predict binding.

[0205] Models of CXCL14 68W binding to target receptors B2R and AT2R: In silico models with B2R as the globular chemokine domain show favorable charge based interactions with the extracellular loops and proximal N-terminus of the receptor (FIG. 9 A-B). The C-terminal helix of the chemokine partially unwinds and inserts into the orthostericbinding pocket in a conformation loosely resembling that of the canonical B2R agonist T-kinin (FIG. 90); CXCL14 W68 reaches the bottom of the binding pocket similarly to the conserved C-terminal Phe of BK and related peptides. CXCL14 residues R60, K63, W64, Y65, and N66 make favorable polar / hydrogen-bonding contacts with B2R pocket residues (FIG. 9D). B2R R196 (critical for kallidin-induced B2R activation coordinates the backbones of CXCL14 residues W64 and N66.

[0206] The geometry of CXCL14 68W binding and insertion differs with AT2R (FIG. 9E-F). In this complex, the C-terminus of 68W adopts a conformation similar to Angll (FIG. 9E) and shares some of its pocket contacts. Key coordination contacts occur between the polar atoms of the backbone, K63, and N66 of CXCL14 68W, and Y103, Y104, Y108ECL1, R182, D279, D297 in the binding pocket of AT2R. The terminal tryptophan (W68) similarly reaches towards the bottom of the binding pocket where it interacts with W269 and other residues canonically mediating Class A GPCR activation.Models of CXCL148AA long peptides from the CXCL14 C terminus

[0207] We modeled short C-terminal truncates (8 amino acids in length) from CXCL14 — terminating in residues 60R through 73R — with B1 R, B2R, AT1 R, and AT2R. Modeling was performed using AlphaFold v3 with the full database present, default configuration, and multiple seeds. Each modeled peptide-receptor pair was evaluated via not only predictor-reported confidence metrics (predicted Local Distance Difference Test or pLDDT, predicted alignment error or PAE) but also by a novel physics-aware Al scoring function, Radial Topological Convolutional Neural Network (RTCNN) trained to predict binding affinity and well-suited for assessing physical validity and favorability of molecular interactions.

[0208] Consistent with our functional data (FIG. 4 and 6 and TABLE 1), 68W scored highest with B2R and AT2R, and was the only variant with an RTCNN score above ~-30 for B2R (a liberal threshold for predicted binding; FIG. 10). 68W and 61 F also scored well with B1 R, defining binding modes correlating with their inhibition of B1 R (FIG. 10). Other interacting candidates identified from modeling include 66N (B1 R), 62I (AT2R), and multiple short truncates with high binding scores for AT1 R (FIG. 10). These peptides are prioritized for in vitro receptor binding and signaling assays.

[0209] The value of Alphafold modeling for hypothesis generation and discovery is demonstrated.Example 568W peptide activates B2R in vivo: vascular leakage and blood pressure regulation

[0210] Rapid B2R activation by bradykinin induces transient opening of the endothelial barrier. Consistent with 68W agonism of B2R, intradermal injection of 68W triggered robust vascular leakage as measured by Evans blue extravasation (Miles assay) (FIG. 11), comparable to that induced by bradykinin. Shorter CXCL14 peptide 61 F and full-length CXCL14 were inactive or less active. The leakage response to 68W was inhibited by the selective B2R antagonist icatibant, confirming receptor dependence. Furthermore, 68W induced leakage in fully bradykinin-deficient mice (Kng 1 / Kng2 double-knockout), establishing that 68W acts through B2R independently of the endogenous bradykinin system.

[0211] B2R is a well-established regulator of vascular tone. Subcutaneous injection of 68W peptide induced rapid, transient suppression of systolic and diastolic blood pressure lasting approximately 20-30 minutes, comparable in magnitude to the effect of bradykinin (FIG. 12). This vasodepressor response was blocked by icatibant and was not elicited by the B2R-inactive peptide 61 F, confirming B2R dependence.

[0212] Palmitoylated CXCL14 peptides enable sustained systemic B2R activation. To extend the duration of activity for in vivo pharmacologic studies, we generated palmitoyl- conjugated variants of 68W and of the full-length C-terminal alpha-helix 77E. Fatty acid- conjugated peptides bind albumin and, after subcutaneous injection, enter lymphatics and achieve sustained plasma levels, as exploited in current GLP-1 peptide therapies. A single subcutaneous injection of palm-68W suppressed blood pressure for approximately 24 hours after a short delay (FIG. 12, center). palm-77E (SEQ ID NO:11) exhibited a longer delay before sustained reduced BP was observed, consistent with a requirement for proteolytic activation. Mutant 77E W68A (SEQ ID NO:36) had no effect on blood pressure, showing the critical role of tryptophan W68 as predicted. In an angiotensin Il-induced hypertension model (continuous Ang II infusion by osmotic minipump), daily subcutaneous palm-68W or palm-77E provided sustained blood pressure normalization (FIG. 12, right).Example 6The pro-form 77E and constitutively active 68W drive distinct in vivo responses

[0213] A prediction of the protease-activation model is that the full-length C-terminal helix (77E, containing the terminal blocking sequence) should be inactive unless cleaved, and thus that its biology may differ from constitutively active 68W. Two lines of evidence currently support this distinction: First, the delay in diastolic BP reduction by palm-77E vs palm68W is consistent with prodrug activation (FIG. 12). Secondly, 77E triggers less local irritation (FIG. 17).

[0214] Reduced local irritation by pro form 77E. Subcutaneous injection of 68W induced robust local irritation behavior (hindlimb scratching directed at the injection site), consistent with acute B2R and potentially MRGPRX2 activation. In contrast, 77E produced markedly reduced scratch responses (68W: 7.5 + / - 0.5 bouts per 20 minutes; 77E: 1.5 + / - 0.5 bouts; p < 0.005; n=2 mice / condition, two independent experiments) (FIG. 17). This is consistent with the in vitro finding that 77E is inactive, and requires activation by injury or stress related proteases.Example 7Chymotryptic proteases cleave at 68W and generate active chemokine and / or activating CXCL14 peptides.

[0215] Our data indicate that the CXCL14 C-terminal alpha-helix contains several bioactive peptides gated by proteolytic processing. The key activating cleavage site at W68 is a canonical chymotryptic site, and additional cleavage sites at W64 and F61 are likewise chymotryptic. Candidate proteases with chymotryptic specificity include kallikrein- related peptidase 7 (KLK7), mast cell chymase (CMA1), granzyme H, cathepsin G, and endothelin-converting enzymes ECE1 and ECE2. Sequential cleavage by serine proteases and ACE or other endo- and ecto-proteases may generate the active CXCL14 68W or 68W peptides.

[0216] To test whether these proteases can generate B2R-active CXCL14 fragments, we cotransfected CHO cells with full-length CXCL14 and active forms of candidate enzymes. Conditioned media containing 300 nM CXCL14 (quantified by ELISA) were applied to CHO cell B2R expressing NFAT reporter cells. Supernatants from CXCL14 coexpressed with active KLK7 or chymase, but not inactive triple mutant KLK7 H57A / D102N / S195A] or CXCL14 alone or enzymes expressed in absence of CXCL14, activated B2R signaling (FIG. 14A). ECE1 co-transfection did not produce receptor activating forms. These data demonstrate that physiologically relevant proteases can process full-length CXCL14 to generate B2R-activating products.

[0217] Mass spectrometric analysis of protease-treated CXCL14 defined cleavage sites generated by each enzyme. LC-ESI-MS analysis of chymase-treated CXCL14 C- terminal peptide (short 70E: (SEQ ID NO:22) FIKWYNAWNE) identified a peptide with m / z consistent with (SEQ ID NO:20) FIKWYNAW, confirming cleavage at the activating W68 site (FIG. 13). Chymase also cleaved at Y65, and ECE1 cleaved at both W68 and W64. KLK7 treatment of full-length CXCL14 released the blocking peptide, corroborated by collision-induced dissociation (CID) fragmentation, confirming cleavage at W68 to liberate the activating truncation.

[0218] In vivo, intradermal injection of active KLK7 elicited robust vascular leakage that was suppressed by systemic administration of the B2R antagonist icatibant (FIG. 14B), consistent with the prediction that endogenous chymotrypic protease activity may locally activate CXCL14 to engage B2R.

[0219] The findings provide a model in which sequential or selective proteolysis by chymotryptic enzymes can sculpt CXCL14 into a spectrum of bioactive fragments with distinct receptor activities: B2R / AT2R-activating (68 W truncates), MRGPRX2-activating (65Y), and B1 R-inhibiting (61 F, 68W) peptides. This protease-gated mechanism would restrict CXCL14 signaling to sites where specific enzymes are activated during inflammation or tissue injury, providing spatial and temporal control of GPCR activation.Example 8Single-cell RNA-seq reveals expression of CXCL14 and BDKRB2 in adventitial fibroblasts

[0220] CXCL14 is a glycosaminoglycan (GAG)-binding chemokine expected to be retained in extracellular matrix, predicting that its signaling would be spatially restricted and would require receptor proximity at sites of expression. Single-cell RNA-seq analyses of human and mouse tissues revealed co-expression of CXCL14 and BDKRB2 within the same populations of PI16+ adventitial fibroblasts — cells with regenerative, regulatory and progenitor potential that orchestrate vascular remodeling and inflammatory responses.

[0221] Spatial transcriptomic analysis (Xenium) confirmed adventitial expression of Cxcl14 and Bdkrb2 in the mouse atherosclerotic aortic root. Standard scRNA-seq of mouse aortic root plaques demonstrated Cxcl14 expression by PH 6+ adventitial fibroblasts, with progressive induction during atherogenesis over weeks of high-fat diet feeding in ApoE- / - mice; notably, Bdkrb2 was progressively downregulated while the pro-inflammatory Bdkrbl was upregulated during atherogenesis. Co-expression of CXCL14 and BDKRB2by PI16+ adventitial fibroblasts was also observed in human coronary artery. RNAscope analysis identified CXCL14-expressing cells surrounding arterioles in human tongue. B2R is also expressed by vascular endothelial cells, where it regulates barrier function. These findings establish the spatial and cellular context for CXCL14- B2R signaling in vivo.

[0222] To extend the to a tissue injury context, we examined publicly available scRNA-seq datasets from human skin and mouse dermis. In normal human skin, UMAP projections showed overlapping expression of CXCL14 and BDKRB2on fibroblasts, mirroring the pattern observed in vascular tissues. Co-expression of Cxcl14 and Bdkrb2 by Pi16+ fibroblasts was also observed in mouse dermis (paw).

[0223] Analysis of gene expression dynamics during human skin wound healing (normal skin, days 1, 7 and 30 post-injury) revealed that CXCL14 and BDKRB2 are both downregulated by day 7, the inflammatory signaling phase, and remain low as fibroblasts transition to contractile (myofibroblast) and fibrotic states. Genes characteristic of “universal” (PI16+) fibroblasts (PI16, CD34, DON) declined in parallel with CXCL14, while the protease inhibitor PI16 itself was re-upregulated during fibrogenesis (days 7-30). Profibrotic TGF-p signaling genes and collagens (TGFB1, COL1A2, COL3A1) were induced at days 7-30, accompanied by the ECM crosslinking gene PLOD1.

[0224] These data suggest that the CXCL14-B2R signaling axis is characteristic of the resting, homeostatic fibroblast state in the skin and is suppressed during wound healing and fibrotic remodeling. The coordinated downregulation of both ligand and receptor during the transition from quiescent to activated fibroblasts is consistent with a role for this pathway in maintaining tissue homeostasis, and its loss during injury may contribute to the progression toward fibrosis.

[0225] We then performed bulk RNA-seq and gene set enrichment analysis (GSEA) on tissues from mice subjected to 1-week Angll infusion with or without daily palm-77E or palm- 68W treatment. Tissues analyzed included heart and suprarenal aorta. Angll induces broad pathogenic gene programs. In heart, 1-week Angll infusion (versus vehicle- treated controls) upregulated inflammatory pathways including TNFa / NF-KB signaling, EMT, collagen / matrix, elastic fibers, angiogenesis and coagulation programs, while suppressing oxidative phosphorylation, fatty acid metabolism and MYC target genes — a metabolic-to-inflammatory transcriptional switch characteristic of cardiac stress. Similar inflammatory and EMT induction, with metabolic pathway suppression, was observed in suprarenal aorta.Example 9

[0226] Peptides 77E and 68W reverse Angll-induced gene programs. Analysis demonstrated that the majority of genes induced by Angll in the heart were suppressed by concurrent 77E treatment, while Angll-suppressed genes were restored. Key reversed genes included inflammatory markers (111b, II6, Egr1 ), extracellular matrix genes (Coll a2), and the cardiac stress marker Nppa, as well as restoration of metabolic genes (Klf15, Cpt1 b, Nr1d2, Timp4). At the pathway level, both 77E and 68W restored oxidative phosphorylation and fatty acid metabolism while suppressing TNFa / NF-KB and inflammatory programs in heart. In Angll stressed heart, the two peptides induce remarkably similar transcriptomic profiles: both suppressed TNFa / NF-KB (NES -2.9 and -2.2, respectively), inflammation (NES -2.4 and -2.3), IFNy response, EMT,collagen / matrix and elastic fiber programs, while restoring oxidative phosphorylation (NES +3.4 and +3.0) and fatty acid metabolism, essentially normalizing the cardiovasculature.

[0227] CXCL14- / - mice show signs of CV stress: endogenous CXCL14 maintains baseline cardiovascular gene signatures: In comparison of WT vs CXCL14- / - mouse tissues, WT mice showed stronger metabolic and reduced fibroinflammatory signatures. Indeed, CXCL14 deficiency mimics Angll stress at baseline: compared to WT mice CXCL14- / - hearts showed transcriptional evidence of metabolic-fibrotic remodeling at baseline (in the absence of Angll): oxidative phosphorylation was suppressed (NES -3.4, FDR < 0.0001), MYC targets V1 were suppressed (NES -2.4), while collagen / ECM pathways were upregulated (NES +2.7), elastic fibers (NES +2.5), EMT (NES +2.2), inflammation (NES +1 .9), and coagulation (NES +1.9) — a pattern that mirrors Angll-stressed wildtype hearts. These data suggest that endogenous CXCL14 is required for normal cardiac metabolic homeostasis, a finding with implications for understanding the chemokine’s physiological role.Example 10CXCL14 peptide 77E protects against Angll-induced cardiac dysfunction

[0228] In a 4-week Ang II infusion model, daily subcutaneous palm-77E fully normalized Ang Il-induced reductions in ejection fraction and fractional shortening, while palm-68W produced an intermediate, partial protective effect. Comparison of 77E-treated and no- Ang II control groups showed no significant difference for either ejection fraction (EF) or fractional shortening (FS), indicating complete functional restoration by the pro-form (15-week male C57BL / 6 mice; 1 .5 mg / kg / day Ang II; n=4-5 / group; two-tailed student t- test) (FIG. 15).Example 11

[0229] CXCL14 peptide 77E attenuates experimental abdominal aortic aneurysm (AAA) (FIGS. 16A-16H).

[0230] In an elastase-induced AAA model, ultrasonography revealed a time-dependent progressive aneurysmal enlargement in intrarenal aorta over the baseline. However, peptide 77E treatment substantially suppressed aneurysmal aortic expansion as indicated by reduced luminal aortic diameter. In histological analyses, 77E treatment inhibited most of key aneurysmal pathologies, including the aortic accumulation of macrophages, T and B lymphocytes and neovessel density, without recognizableimpact on medial elastin and smooth muscle destruction. These results indicate that 77E is protective against experimental AAAs.Conclusions

[0231] These studies identify CXCL14 as a protease-activated ligand for the bradykinin B2 receptor and define a previously unrecognized chemokine-protease-GPCR signaling axis that integrates immune and vascular biology. The principal findings are: (1) in vitro assays establish B2R and AT2R as receptors for proteolytically processed CXCL14; (2) the 15-amino-acid peptide 68W is a potent dual B2R / AT2R agonist that also inhibits B1 R; (3) CXCL14 and B2R are both expressed in adventitial fibroblasts positioned for local vascular and ECM control; (4) both 77E and 68W reverse Angll-induced pathogenic gene programs at the transcriptom ic level: and the pro-form 77E achieves full cardioprotection; (5) CXCL14 deficiency alters basal cardiac gene programs; and (6) chymotryptic proteases KLK7 and chymase activate CXCL14 generating B2R-active CXCL14 fragments, establishing a protease-activation mechanism.

[0232] The canonical B2R agonist bradykinin is a circulating peptide derived from plasma kininogens through kallikrein activity, acting as a systemic vasoactive hormone. In contrast, CXCL14 is a GAG-binding chemokine predicted to be retained in extracellular matrix at sites of expression. The CXCL14-B2R axis therefore represents a mechanistically distinct, spatially restricted pathway for B2R activation - a local protease-gated system that complements the systemic bradykinin pathway. Proteasegated activation ensures receptor engagement at sites of tissue stress, while systemic constitutive activation may alter signaling in vulnerable but non-stressed tissues, with undesirable consequences. As one example, the pro-form avoids irritation at the s.c. injection site of the peptide.

[0233] Dual B2R / AT2R agonism and B1 R inhibition. The finding that 68W simultaneously activates B2R and AT2R while inhibiting B1 R has important biological implications. B2R activation generally promotes vasodilation, vascular permeability and endothelial repair, while AT2R activation is broadly anti-inflammatory, anti-fibrotic and cardioprotective. B1 R, in contrast, drives sustained pro-inflammatory signaling. By activating B2R and AT2R while suppressing B1 R, the combined pharmacologic profile of CXCL14-derived peptides favors resolution-phase vascular biology. The fact that a single proteolytic event (cleavage at W68) simultaneously unlocks both B2R and AT2R agonism, while the blocking peptide prevents all receptor engagement, suggests that this dual-receptor activation may be the physiologically intended output.

[0234] The pro-form / active-form distinction has therapeutic relevance. A protease-dependent pro-drug based on the 77E sequence harnesses endogenous protease activity at sitesof vascular stress or injury for tissue-selective B2R / AT2R activation. The reduced local irritation observed with 77E versus 68W at the injection site is consistent with controlled, protease-dependent release rather than systemic bolus activation, and supports feasibility of chronic administration.

[0235] CXCL14 as an endogenous cardiovascular regulator. The observation that CXCL14 / _hearts display a basal metabolic-fibrotic transcriptom ic signature resembling Angll- stressed wild-type hearts (suppressed oxidative phosphorylation, upregulated collagen / ECM programs) indicates that endogenous CXCL14 is required for normal cardiac metabolic homeostasis, and is not merely serving as a stress-responsive factor. These genetic data complement the pharmacologic studies and support a physiological role for the CXCL14 axis in cardiovascular homeostasis.

[0236] The identification of multiple cleavage sites within the CXCL14 C-terminal helix that generate peptides with distinct receptor activities suggests a “protease-encoded signaling grammar” in which local enzyme cascades determine the functional output of the chemokine.. KLK7-mediated cleavage after W68 generates potent B2R / AT2R agonists; cleavage after Y65 could release MRGPRX2-activating short peptides with potential for mast cell activation; cleavage at F61 generates B1 R-inhibitory fragments. Sequential or combinatorial cleavage by different proteases could therefore produce complex, context-dependent signaling and peptides with different signaling strengths and specificities. The proteases identified: KLK7 and chymase, show distinct cell-type and tissue expression, KLK7 in squamous epithelia and fibroblasts, chymase in mast cell granules. This cellular distribution provides a potential mechanism for tissuespecific CXCL14 activation.

[0237] The pharmacologic profiles demonstrated here are relevant for therapeutic applications.B2R agonism and AT2R agonism are individually associated with cardioprotection, vasodilation, and anti-fibrotic effects, and the combined profile of 77E offers advantages over selective agonists. Indications include hypertension, cardiac hypertrophy and fibrosis, vascular remodeling, and acute ischemic injury. The observation that 77E achieves blood pressure reduction comparable to 68W while also normalizing cardiac function and gene programs positions the pro-form as a candidate for chronic cardiovascular disease management. The protease-dependent activation mechanism may enable tissue-selective activity, reducing off-target effects of systemic B2R agonism.Example 12

[0238] AT2R-mediated suppression of Angll vasopressor responses. AT2R (Agtr2) deficient mice exhibit heightened vasoconstrictive responses to Angll compared to wild-typecontrols, establishing AT2R as a physiological antagonist of acute AT1 R-mediated vasoconstriction. We adapt this model (Hein et al., 1995; Ichiki et al., 1995) to determine if CXCL14 peptides inhibited the vasopressor response to exogenous Angll and to assess the role of AT2R.

[0239] Methods: Mice are treated with icatibant to block B2R, and captopril, an angiotensin I converting enzyme (ACE) inhibitor to eliminate endogenous Angll as described for the model. Initial studies define the dose of Angll that enhances blood pressure after subcutaneous injection. Subsequently, mice are administered CXCL14 peptides or control peptides as for FIG. 12 with or without Angll. Blood pressure is monitored as above. Positive control experiments assess the inhibition of Angll pressor responses by the selective AT2R agonist C21. Reduced Angll pressor responses in peptide- treated wild type mice, but not in mice pre-treated with the ATR2 antagonist PD123319, indicate physiologic AT2R activation by the test CXCL14 peptides (e.g. 68W or CXCL14 68W).

[0240] Endogenous CXCL14 modulation of AT1R-driven pressor responses. Basal levels of endogenous CXCL14 activation may moderate AT 1 R vasopressor activity as well. After establishing optimal conditions for assaying AT2R effects, we compare the Angll pressor response in CXCL14- / - vs WT mice. If the acute Angll pressor response is enhanced in CXCL14 deficient mice, and suppressed with 68W administration, we will conclude that endogenous CXCL14 has a significant role in maintaining vascular tone through moderation of AT1 R vasoconstriction.

[0241] CXCL14 in vascular injury — cuffed femoral artery model AT2R inhibits neointimal proliferation and inflammation in response to non-occlusive arterial injury induced by perivascular cuffing of the femoral artery in mice. B2R supports endothelial repair, and may act synergistically with AT2R to enhance reparative responses. CXCL14, through activation of both B2R and AT2R, may improve vascular healing.

[0242] Method: To test the role of endogenous CXCL14, CXCL14- / - and co-housed WT mice are subjected to surgical placement of a non-occlusive cuff around the femoral artery as described. On day 14, arteries are assessed for neointimal hyperplasia, smooth muscle actin expression, inflammatory cells (CD45, F4 / 80) and inflammatory gene expression by PCR (e.g. IFNgamma, IRF1). To test the potential of CXCL14 peptides to moderate injury, mice are treated with active peptides administered continuously by Alzet minipump, implanted at the time of surgery. Fatty acid conjugation of peptides may enhance half life permitting administration by periodic subQ injection. We are currently testing the efficacy of palmitoyl-68W. If endogenous CXCL14 or CXCL14peptides enhance or alter physiologic repair, the role of B2R and AT2R is evaluated by co-infusion of icatibant or AT2R antagonist PD123319.

[0243] Tests of endogenous CXCL 14 activation by candidate proteases in vivo

[0244] Methods: Vascular leakage: Active and control inactive proteases are injected subcutaneously concurrently or 20 min after i.v. Evan's blue administration as above. Predicted B2R dependence is assessed by determining the effects of B2R inhibitor icatibant.Vasodepressor responses: Subcutaneous injection of 68W induces a robust reduction in blood pressure (FIG. 12). Candidate proteases, by activating endogenous CXCL14, may yield similar responses. Active or control proteases are injected subcutaneously or i.p. followed by monitoring of blood pressure. Predicted B2R dependence is assessed by inhibition with icatibant. In both models, comparison of CXCL14+ / + with littermate CXCL14- / - mice, if indicated in Kng1 / Kng2- / - hosts, will determine whether observed effects are dependent on endogenous CXCL14. Additional candidate proteases identified by mass spectrometry are evaluated using the in vitro co-transfection PRESTO-Tango assay described in Example 7 and FIG. 14A.

[0245] CXCL14 effects on endothelial cell function (in vitro). In vitro assays of CXCL14 effects on endothelial cells: Here, we define the impact of CXCL14 peptides on endothelial cell function and test the hypothesis that these effects are mediated through activation of B2R and / or AT2R. Both receptors influence endothelial homeostasis through overlapping pathways. While chronic B2R stimulation supports endothelial integrity, acute B2R activation is classically associated with transient junctional disassembly, transient increases in reactive oxygen species (ROS), and robust nitric oxide (NO) production via eNOS activation. AT2R activation typically enhances NO bioavailability, promotes antioxidant effects, and supports barrier integrity through VE-cadherin stabilization and inhibition of inflammatory signaling.

[0246] Methods: To evaluate these functional outcomes, we culture bEnd.3 cells (a mouse endothelial line used for barrier studies to confluence on collagen-coated transwell inserts and glass coverslips. Peptides (e.g., 68W, CXCL14 68W) or controls (bradykinin, C21) are applied for 10-60 minutes. Barrier function is quantified by FITC- dextran permeability across transwell monolayers and by immunofluorescence analysis of junctional proteins (VE-cadherin, ZO-1 , claudin-5, occludin). In parallel, we measure real-time NO production using DAF-FM diacetate and ROS levels (oxidative stress) using DCFDA (2',7'-dichlorodihydrofluorescein diacetate) in both bEnd.3 and primary human aortic endothelial cells (HAECs, Promocell), to ensure translational relevance.To determine receptor-specific mechanisms, assays are performed in the presence or absence of the B2R antagonist icatibant and the AT2R antagonist PD123319.

[0247] CXCL14 and CXCL14 derived peptides in cutaneous wound healing. To assess the effects of the CXCL14 peptides on cutaneous wound healing, we adapt and extend the validated preclinical mouse model of wound healing utilized in Harrison et al. (Harrison et al., 2024). Full-thickness excisional wounds are generated on the dorsal skin of adult Balb / c mice using a standardized 6 mm biopsy punch. To prevent rapid contractionbased closure typical in murine skin, silicone splints are sutured around each wound to better replicate human healing dynamics through re-epithelialization. Mice are randomly assigned to receive topical applications of CXCL14 peptides or vehicle control, or known selective AT2R modulators (e.g., Compound 21 as positive control, PD123319 as negative control). Treatments are applied daily until euthanasia at post-wounding days 7 and 10. Primary endpoints include: (1) rate of re-epithelialization as assessed by digital imaging and planimetric analysis, (2) histological assessment of wound maturation, collagen deposition (Picrosirius Red staining and collagen kill ratio), vascular density (CD31 immunohistochemistry), and leukocyte infiltration. Additionally, quantitative RT-PCR is performed on wound tissues to profile gene expression signatures of fibrosis, angiogenesis, and immune modulation.Therapeutic Indications

[0248] CXCL14 peptides are useful in the treatment of diseases where AT2R has protective roles including but not limited to hypertensive end-organ damage (Fatima et al., 2021 ; Molla and Shiferaw, 2017; Sumners et al., 2015), reduction of renal damage independent of blood pressure changes (Carey et al., 2000), reduction of infarct size and enhancement of cardiac function after myocardial infarction, protection against cerebral hemorrhage and vascular damage (Fatima et al., 2021 ; Molla and Shiferaw, 2017; Sumners et al., 2015), and aortic aneurysm (Lange et al., 2018). AT2R is further implicated in cutaneous wound healing (Harrison et al., 2024).

[0249] CXCL14 peptides are further useful in the treatment of additional diseases where B2R has regulatory or protective roles including but not limited to opening of the blood-brain barrier to enhance anti-tumor drug delivery (Emerich et al., 2001).

Claims

What is Claimed is:

1. An active peptide of from about 8 to 68 amino acids comprising a portion of the C-terminal region of SEQ ID NO:1, which C-terminal region comprises at least the amino acid sequence SEQ ID NO:40, or SEQ ID NO:12, and which peptide activates one or both of Angiotensin II Type 2 receptor (AGTR2) and Bradykinin B2 receptor (BDKRB2).

2. The peptide of claim 1 , wherein the peptide is effective in reducing hypertension when administered to an individual in need thereof.

3. The peptide of claim 1 , wherein the peptide is effective in reducing risk of rupture of aneurysm when administered to an individual in need thereof.

4. The peptide of claim 1 , wherein the peptide is effective in reducing risk of heart failure when administered to an individual in need thereof.

5. The peptide of claim 1 , wherein the peptide is effective in regulating vascular permeability and tone when administered to a subject in need thereof.

6. The polypeptide of any of the previous claims, wherein the polypeptide selectively activates one or both of Angiotensin II Type 2 receptor (AGTR2) and Bradykinin B2 receptor (BDKRB2) and does not activate Angiotensin II Type 1 receptor (AGTR1) or Bradykinin B1 receptor (BDKRB1).

7. The polypeptide of any of the previous claims, wherein the polypeptide selectively binds to one or both of Angiotensin II Type 2 receptor (AGTR2) and Bradykinin B2 receptor (BDKRB2).

8. The polypeptide of any of the previous claims, wherein the polypeptide inhibits Bradykinin B1 receptor (BDKRB1) signaling.

9. The polypeptide of any of the previous claims, which is sufficient to activate BDKRB2 / AGTR2, and inhibit BDKRB1 signaling.

10. The peptide of any of the previous claims, wherein the peptide lacks the inhibitory terminal sequence of CXCL14, SEQ ID NO:37, NEKRRVYEE.

11. The peptide of claim 10, comprising or consisting of SEQ ID NO:8, KLQSTKRFIKWYNAW, or a variant thereof.

12. The peptide of claim 10, comprising or consisting of SEQ ID NO:9, 10, 12, 13, 32, 14, 15, 16, 17, 18, 19, 20, 21 , or 22.

13. The peptide of claim 10, comprising or consisting of SEQ ID NO:33.

14. A peptide precursor to the polypeptide of any of claims 1-9 or 11-13, wherein the precursor is activated by cleavage.

15. The peptide of claim 14, comprising or consisting of SEQ ID NO:11 or a variant thereof.

16. The peptide of claim 15, comprising or consisting of SEQ ID NO:23-31 .

17. A polypeptide of any of the previous claims, wherein the polypeptide comprises one or more modifications.

18. The peptide of claim 17, wherein the modification is selected from substitution of a natural amino acid with alpha-aminoisobutyric acid (Aib), (1-Nal) 1 -naphthylalanine, (2-thienyl)-Ala (Thi), methyl-tyrosine, ornithine, or D-enantiomers of amino acids.

19. The peptide of claim 17, wherein the modification comprises conjugation to a fatty acid or diacid.

20. The peptide of claim 19, wherein the fatty acid is myristic acid, lauric acid, palmitic acid, stearic acid, octadecanedioic acid, or hexadecanedioic acid.21 . The peptide of claim 17, wherein the modification comprises pegylation.

22. The peptide of claim 17, wherein the modification comprises one or both of amidation at the C-terminus and acetylation at the N terminus.

23. The peptide of claim 17, wherein the modification comprises fusion to an Fc region sequence.

24. A pharmaceutical composition comprising a polypeptide of any of claims 1-23.

25. The pharmaceutical composition of claim 24 in a unit dosage form.

26. An antibody that specifically binds to a polypeptide according to any of claims 1- 23.

27. A polynucleotide that encodes a polypeptide according to any of claims 1-23.

28. A vector comprising a polynucleotide of claim 27.

29. A polypeptide, pharmaceutical formulation, antibody or polynucleotide of any of claims 1 -28, for use in a method of treatment for an individual in need thereof.

30. The use of claim 29, wherein the method of treatment is for cardiovascular dysfunction.

31. The use of claim 30, wherein the cardiovascular dysfunction is selected from hypertension, vascular complications in sepsis, eclampsia, ARDS, ischemic injury, cardiac remodeling, aneurysm, stroke, and vascular complications of inflammatory diseases.

32. The use of claim 30, wherein the cardiovascular dysfunction is hypertension.

33. The use of claim 30, wherein the cardiovascular dysfunction is aortic aneurysm.

34. The use of claim 29, wherein the method of treatment is for controlling epithelial barrier integrity for inflammatory and autoimmune diseases selected from IBD, asthma, and neuroinflammation.

35. The use of claim 29, wherein the treatment inhibits fibrosis.

36. The use of claim 29 wherein the treatment enhances wound healing.

37. A method for selective activation of one or both of AGTR2 and BDKRB2, the method comprising contacting the receptor(s) with an effective dose of a peptide of any of claims 1-25.

38. The method of claim 37, wherein the peptide is administered to an individual in need thereof.

39. The method of claim 38, wherein the individual suffers from a cardiovascular dysfunction.

40. The method of claim 39, wherein the individual suffers from hypertension.

41. The method of claim 39, wherein the individual suffers from an aortic aneurysm.

42. The method of claim 39, wherein the individual is at risk of heart failure.

43. The method of any of claims 37-42, further comprising administering a second therapeutic agent to the individual.

44. A method of screening candidate agents for activity in modulating RAAS system, the method comprising determining the activity of a candidate agent in modulating CXCL14 activity.

45. The method of claim 44, wherein the candidate agent is an antibody, polypeptide, aptamer, or small molecule.